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Lipids are essential building blocks of the cell. Membrane lipids form a 
phospholipid bilayer surface, separate cells from the outside environment, and 
enclose compartments of organelles with distinct shapes and functions in the 
cytoplasm. Phospholipids are the most abundant lipids in cell membranes, and 
the major phospholipids in the membranes of S. cerevisiae and all eukaryotes 
are phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylinositol (PI), phosphatidylserine (PS), and cardiolipin (CL). 
Phospholipid synthesis is required for membrane biogenesis and is critical for 
nearly all aspects of cellular activities.  
Regulation of the synthesis of phospholipids is a highly coordinated event, which 
has been well studied in yeast (Carman and Henry, 1999; Greenberg and Lopes, 
1996; Henry et al., 2012b). Expression of many of the genes encoding 
phospholipid synthesis enzymes is controlled via a conserved inositol-responsive 
upstream activating sequence (UASINO) in their promoters in response to inositol 
availability. Coordinated regulation of synthesis of phospholipids by inositol 
underscores the importance of regulation of synthesis of inositol, a precursor of 
inositol-containing lipids. To explore novel mechanisms underlying regulation of 
synthesis of phospholipids, I carried out three projects described in this 
dissertation to address the current knowledge gaps in phospholipid biosynthesis. 
First, in addition to the well-characterized regulatory circuits controlled by the 
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trans-acting factors Ino2, Ino4, and Opi1, I discovered that inositol 
pyrophosphates are novel regulators of synthesis of inositol and phospholipids. 
This demonstrates a new level of complexity of inositol metabolism and 
phospholipid synthesis. Second, there are very few reported studies of the 
regulation of inositol synthesis in human cells despite the importance of inositol. I 
demonstrated for the first time that decreased inositol biosynthesis leads to 
increased GSK-3α  phosphorylation in neuronal cells. Third, although synthesis of 
most phospholipids (PC, PE, PS and PI) is responsive to exogenous inositol, the 
synthesis of CL is an exception, as the genes in the CL biosynthetic pathway do 
not contain the UASINO motif. I showed that the CL-specific phospholipase is the 
most highly regulated gene in the pathway, and that its regulation affects energy 
dynamics. The findings in this study have significant implications for the life-
threatening disorder Barth syndrome. In summary, I used both yeast and 
mammalian cells for my dissertation research and elucidated three novel 
molecular mechanisms underlying the regulation of phospholipid synthesis, 
which identify new directions for potential research in this field. 
 
1. SYNTHESIS OF INOSITOL AND PHOSPHOLIPIDS 
1.1 Inositol metabolism 
Inositol, a ubiquitous six-carbon cyclitol, is an essential metabolite and a 
precursor for inositol phosphates, phosphoinositides, and inositol sphingolipids 
(Bachhawat et al., 1995b). These inositol-containing molecules play crucial roles 
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in gene expression, signal transduction, lipid signaling, and membrane 
biogenesis. The regulation of inositol-related signaling modulates various cell 
functions, such as cell growth, apoptosis, endocytosis, neuronal plasticity, and 
membrane trafficking (Greenberg and Lopes, 1996; Michell, 2011; York et al., 
2001). The involvement of inositol and its derivatives in such essential cellular 
processes reflects the importance of the regulation of inositol metabolism.  
In all eukaryotic organisms, there are three ways to obtain inositol (Fig. 1-1): (i) 
uptake via inositol transporters, (ii) de novo synthesis of inositol from glucose-6-
phosphate (G6P) by inositol-3-phosphate synthase (Ino1), and (iii) turnover of PI, 
which is hydrolyzed by phospholipase C.  Inositol de novo synthesis is carried 
out in two steps, as shown in Fig. 1-1. Ino1 is the rate-limiting enzyme and 
catalyzes the isomerization of glucose-6-phosphate (G6P) to inositol-3-
phosphate. This process is a three-step reaction, which is well characterized 
(Eisenberg, 1967; Kindl and Hoffmann-Ostenhof, 1964; Loewus and Kelly, 
1962b). The Ino1 protein contains three domains: a central domain containing N- 
and C-termini that interact with monomers, an NAD-binding domain, and a 
catalytic domain that binds the substrate G6P (Strausberg et al., 2002). The 
native Ino1 enzyme is a homotrimer in mammalian cells and a homotetramer in 
yeast and plant cells (Seelan et al., 2009). The 1.8 kb mammalian Ino1 mRNA is 
diversely expressed in tissues, including the testes, heart, placenta, pancreas 
and brain (Guan et al., 2003). Three putative isoforms were reported (Strausberg 
et al., 2002). The recently identified γ-form of Ino1 expressed in most tissues was  
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Figure 1-1:  Inositol metabolism. Inositol can be taken up from the extracellular 
environment or synthesized de novo or via recycling. In de novo synthesis, Ino1 
catalyzes the rate-limiting step of isomerization of glucose-6-phosphate (G-6-P) to 
inositol-3-phosphate (I-3-P). Transcription of INO1 is repressed by Opi1 when inositol 
is abundant. The inositol pool is used for the synthesis of PI, catalyzed by Pis1. PI is 
further phosphorylated to phosphatidylinositol phosphates. PI(4,5)P2 (PIP2 in the 
figure) is hydrolyzed to IP3 and diacylglycerol (DAG, not shown). IP3 can be serially 
dephosphorylated to recycle inositol or further phosphorylated into inositol 
polyphosphates by Ipk2 and Ipk1. Kcs1 converts IP5 and IP6 to inositol 
pyrophosphates. 
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suggested to be a negative regulator of Ino1 activity (Seelan et al., 2009). 
1.2 Regulation of synthesis of inositol and phospholipids 
Regulation of synthesis of inositol and phospholipids in S. cerevisiae has been 
well-characterized. Expression of genes involved in their biosynthetic pathways is 
coordinated and controlled by the conserved motif (UASINO) in their promoter 
regions (Carman and Henry, 1999; Greenberg and Lopes, 1996; Henry et al., 
2012b). Exogenous inositol greatly affects the biosynthesis of inositol and 
phosphlipids. Supplementation with exogenous inositol leads to increased PI 
synthesis and decreased synthesis of most of other phospholipids (Gaspar et al., 
2006b; Loewen et al., 2004). The mechanism underlying this response to 
exogenous inositol has been characterized (Carman and Henry, 2007b; Loewen 
et al., 2004). Inositol potently regulates biosynthesis of inositol and phospholipids 
by controlling transcription of INO1 and other UASINO-containing genes through 
the transcriptional repressor Opi1 (Greenberg et al., 1982). When inositol is 
limiting, Opi1 interacts with the VAMP-associated protein (VAP) Scs2 and 
phosphatidic acid (PA) on the pheriphery of the nucleus and remains tethered in 
the cytoplasm (Loewen et al., 2004).  When inositol is abundant, PA levels are 
consumed for the synthesis of PI. The decrease in PA levels disrupts stability of 
Opi1 on the pheriphery of the nucleus, leading to translocation of Opi1 into the 
nucleus. In the nucleus, Opi1 interacts with the transcriptional activator complex 
Ino2-Ino4 and represses transcription of INO1 as well as other genes whose 
promoters contain the UASINO motif (Loewen, 2012; Loewen et al., 2004).  
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Figure 1-2: Synthesis of phospholipids. Phospholipids are synthesized from 
phosphatidic acid (PA). PA is converted to CDP-diacylglycerol (CDP-DAG), which 
is utilized for synthesis of phosphatidylinositol (PI), cardiolipin (CL), and 
phosphatidylserine (PS). Phosphatidylethanolamine (PE) is synthesized by 
decarboxylating PS. Three sequential methylation steps convert PE to PC. PC and 
PE can also be synthesized via the Kennedy pathway from DAG. The genes 
highlighted in red contain the UASINO motif in their promoters and are 
transcriptionally controlled by inositol.   
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The Ino2-Ino4-Opi1 regulatory mechanism also controls the transcription of 
phospholipid biosynthetic genes. The trans-acting factors Ino2, Ino4, and Opi1 
exert regulatory effects on the cis-acting inositol-responsive upstream activating 
sequence (UASINO) (Bachhawat et al., 1995b), which is found in the promoters of 
more than 30 genes in phospholipid metabolic pathways (Carman and Han, 2011; 
Chen et al., 2007; Henry et al., 2012a). Coordinated expression of the genes 
involved in phospholipid synthesis highlights the importance of inositol 
metabolism in the regulation of membrane biogenesis. 
1.3 Importance of inositol metabolism in human health. 
Although inositol from diet can cross the blood-brain barrier and enter the 
cerebrospinal fluid and brain parenchyma, this process is very slow (Aukema, 
1994). Inositol levels in the brain primarily depend on PI turnover and de novo 
synthesis (Williams et al., 2002). The brain maintains a high level of free inositol 
(5–50 mM), which is about 100 times higher than in the blood and other tissues 
(Palmano et al., 1977; Sherman et al., 1977; Stokes et al., 1983; Wong et al., 
1987). The large inositol pool in the brain may be associated with active inositol-
related signaling. Changes in inositol levels may reflect a modulated signal 
transduction in the control of neurotransmitter systems and neuronal functions. 
Stable inositol levels are critical for normal brain function, and altered inositol 
levels in the brain are associated with psychiatric and neurological problems (Shi 
et al., 2006). For example, levels of inositol are altered in the brains of patients 
with Down syndrome (Acevedo et al., 1997; Berry et al., 1995), stroke (Rumpel et 
al., 2003), bipolar disorder (Belmaker et al., 2002; Shimon et al., 1997), and 
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suicide victims (Shimon et al., 1997). Interestingly, two FDA-approved drugs for 
the treatment of bipolar disorder, lithium and valproic acid (VPA), have the 
common biological property of depleting intracellular inositol (Azab et al., 2007; 
Berridge et al., 1989; Harwood and Agam, 2003; Klein and Melton, 1996; Li and 
Jope, 2010; Vaden et al., 2001). Although therapeutic actions of these two FDA-
approved drugs have not been elucidated, the common effect of inositol 
depletion resulted from two disparate drugs suggests that this may be 
therapeutically relevant. Understanding the regulation of inositol metabolism may 
have important implications for the therapeutic mechanism of drugs in bipolar 
disorder as well as other disorders in which inositol levels may play a role. 
2. CL SYNTHESIS AND FUNCTIONS 
2.1 CL de novo synthesis and remodeling 
CL is a unique phospholipid that is predominantly synthesized and localized in 
mitochondrial membranes (Hostetler et al., 1972; Joshi et al., 2009). Following de 
novo synthesis, CL undergoes remodeling in which acyl chains are exchanged in 
a deacylation-reacylation cycle. As depicted in Fig. 1-3, the committed step of CL 
synthesis is catalyzed by Pgs1, in which CDP-DAG and glyerol-3-phosphate are 
converted to phosphatidylglycerolphosphate (PGP) (Chang et al., 1998a), which 
is dephosphorylated to phosphatidylglycerol (PG) by the PGP phosphatase Gep4 


















Figure 1-3: CL de novo synthesis and remodeling in S. cerevisiae. Pgs1 
catalyzes the committed step of CL synthesis by converting CDP-DAG to 
phosphatidylglycerolphosphate (PGP), which is dephosphorylated to 
phosphatidylglycerol (PG) by the GEP4-encoded PGP phosphatase. CL 
synthase, encoded by CRD1, condenses PG and CDP-DAG to form CL. CL 
synthesized de novo has primarily saturated acyl chains (CLsat). CLsat is 
deacylated by the CL-specific phospholipase Cld1 to monolysocardiolipin 
(MLCL), which is reacylated by tafazzin (the TAZ1 gene product) to CL 
containing more unsaturated acyl chains (CLunsat). 
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the final step of CL de novo synthesis by condensing PG and CDP-DAG to form 
CL with primarily saturated acyl chains (Chang et al., 1998b; Jiang et al., 1997; 
Tamai and Greenberg, 1990; Tuller et al., 1998).  Following the de novo 
synthesis of CL on the matrix side of the inner mitochondrial membrane, CL 
undergoes remodeling in which acyl chains are exchanged. In this process, CL is 
deacylated to monolysocardiolipin (MLCL) by the CL-specific phospholipase Cld1 
on the matrix side of the inner mitochondrial membrane (Baile et al., 2013; 
Beranek et al., 2009). MLCL is reacylated by the transacylase Taz1 in the 
mitochondrial periphery (Brandner et al., 2005; Claypool et al., 2008a; Gu et al., 
2004; Testet et al., 2005). Remodeled CL has more unsaturated acyl chains than 
CL synthesized de novo (Beranek et al., 2009; Gu et al., 2004; Vaz et al., 2003; 
Xu et al., 2003). 
2.2 CL cellular functions and related human disorders 
As the signature lipid of mitochondria, CL comprises about 15% of total 
mitochondrial phospholipids (Jakovcic et al., 1971) and interacts with a wide 
range of mitochondrial proteins (Claypool, 2009; Klingenberg, 2009; Schlame 
and Ren, 2009; Schlame et al., 2000), including the ADP/ATP carrier (Beyer and 
Klingenberg, 1985; Claypool et al., 2008b) and respiratory complexes (Eble et al., 
1990; Lange et al., 2001; Palsdottir et al., 2003; Shinzawa-Itoh et al., 2007). CL-
protein interactions stabilize respiratory chain supercomplexes (Pfeiffer et al., 
2003; Zhang et al., 2002) and promote supramolecular associations between the 
ADP/ATP carrier and respiratory supercomplexes (Claypool et al., 2008b). 
Therefore, it is not surprising that mitochondrial respiration and energy 
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production are highly correlated with CL biosynthesis (Claypool et al., 2008b; 
Gohil et al., 2004; Jiang et al., 2000). Interestingly, CL deficiency also leads to 
deficiencies in diverse cellular functions other than mitochondrial bioenergetics, 
including mitochondrial dynamics (DeVay et al., 2009; Joshi et al., 2012), 
mitochondrial protein import (Gebert et al., 2009; Jiang et al., 2000), cell wall 
biogenesis (Zhong et al., 2005; Zhong et al., 2007), vacuolar function and 
morphology (Chen et al., 2008), cell cycle (Chen et al., 2010), aging (Zhou et al., 
2009), and apoptosis (Gonzalvez and Gottlieb, 2007; Houtkooper and Vaz, 2008; 
Schug and Gottlieb, 2009).  
A deficiency in CL reacylation resulting from mutations in tafazzin leads to the 
life-threatening disorder Barth syndrome (BTHS). Although BTHS is the only 
known disorder genetically linked to CL, perturbation of CL content is also 
observed in other cardiac pathologies, such as diabetic cardiomyopathy, heart 
failure, and ischemia/reperfusion injury (Chicco and Sparagna, 2007; Han et al., 
2007; Lesnefsky et al., 2009). Because CL mediates a plethora of cellular 
activities and is associated with many human diseases, understanding how CL 
synthesis is regulated will benefit our fundamental knowledge of CL functions 
and shed light on potential therapeutic targets of diseases associated with CL 
deficiency.   
3. PROJECT OUTLINE 
The goal of the research described in this dissertation is to characterize and 
identify novel regulators of the synthesis of phospholipids. To explore 
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mechanisms underlying the regulation of phospholipid synthesis, I have carried 
out the following studies:  
The studies described in Chapter 2 show that inositol pyrophosphates regulate 
inositol biosynthesis. I found that inositol pyrophosphate-deficient cells exhibit 
inositol auxotrophy, decreased intracellular inositol, and decreased 
phosphatidylinositol due to defective transcription of INO1, which encodes the 
rate-limiting enzyme inositol-3-phosphate synthase, Ino1. This is the first 
demonstration that inositol pyrophosphates are required for synthesis of inositol 
and phospholipids.  
In Chapter 3, I described the effects of CLD1 deletion on tafazzin-deficient yeast 
cells. The cld1Δ mutant has decreased unsaturated CL, but the CL/MLCL ratio is 
similar to that of wild type cells. I showed that deletion of CLD1 rescues growth 
and lifespan defects in the tafazzin mutant. This suggests that tafazzin deficiency 
is caused by the decreased CL/MLCL ratio, not by a deficiency in unsaturated CL. 
I further showed that CLD1 expression is increased during respiratory growth and 
regulated by the HAP transcriptional activation complex. Overexpression of 
CLD1 leads to decreased mitochondrial respiration and growth and instability of 
mitochondrial DNA. These findings have implications for BTHS, a mitochondrial 
disease resulting from mutations in human tafazzin. 
In Chapter 4, I described the consequences of perturbation of inositol 
biosynthesis in neuronal cells. Using an inositol-depleting drug VPA, I found that 
depletion of intracellular inositol was concomitant with GSK3α phosphorylation. 
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Using shRNAs targeting the human INO1 gene to knock down human INO1 
expression in a neural cell line, I determined that GSK3α phosphorylation was 
elevated in the INO1 knockdown cells. Interestingly, GSK3β phosphorylation was 
not altered. We conclude that perturbation of inositol biosynthesis in neural cells 
leads to phosphorylation of GSK3α.  
While the studies described in the above chapters showed new regulators and 
novel findings in phospholipid biosynthesis, many interesting questions remain 






REGULATION OF INOSITOL METABOLISM IS FINE-TUNED BY INOSITOL 
PYROPHOSPHATES IN SACCHAROMYCES CEREVISIAE 
The work described in this chapter has been published in the Journal of 
Biological Chemistry 288: 24898-24908, 2013. 
INTRODUCTION 
Inositol, a ubiquitous six-carbon cyclitol, is an essential metabolite and a 
precursor of inositol phosphates, phosphoinositides, and sphingolipids (Carman 
and Han, 2011; Henry et al., 2012a). These inositol-containing molecules play 
crucial roles in gene expression (Shen et al., 2003; Steger et al., 2003), signal 
transduction (Strahl and Thorner, 2007), lipid signaling (Kutateladze, 2010), and 
membrane biogenesis (van Meer et al., 2008a). The regulation of inositol-related 
signaling modulates various cell functions, such as cell growth, apoptosis, 
endocytosis, neuronal plasticity, and membrane trafficking (Greenberg and 
Lopes, 1996; Henry et al., 2012a; York et al., 2001). The involvement of inositol 
and its derivatives in such essential cellular processes reflects the importance of 
the regulation of inositol metabolism.  
In eukaryotes, inositol can be obtained from exogenous inositol via inositol 
transporters and from the de novo synthesis of inositol from glucose. Inositol 
biosynthesis is carried out in two steps, of which the Ino1-catalyzed conversion of 
glucose-6-phosphate to inositol-3-phosphate is rate-limiting (Loewus and Kelly, 
1962a). In Saccharomyces cerevisiae, exogenous inositol potently controls 
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inositol biosynthesis by regulating INO1 transcription through the transcriptional 
repressor Opi1 (Greenberg et al., 1982). In the absence of exogenous inositol, 
Opi1 is sequestered on the pheriphery of the nucleus by interaction with the 
VAMP-associated protein (VAP) Scs2 and with phosphatidic acid (PA) (Loewen 
et al., 2004).  In response to exogenous inositol, PA levels are depleted as PA is 
utilized in the synthesis of phosphatidylinositol (PI). This results in the rapid 
translocation of Opi1 to the nucleus, where it inhibits the basic helix-loop-helix 
(bHLH) transcriptional activator complex Ino2-Ino4 and represses INO1 
transcription (Loewen, 2012; Loewen et al., 2004). This regulatory mechanism 
also controls the transcription of phospholipid biosynthetic genes. The trans-
acting factors Ino2, Ino4, and Opi1 exert regulatory effects on the cis-acting 
inositol-responsive upstream activating sequence (UASINO) (Bachhawat et al., 
1995b), which is found in the promoters of more than 30 genes in phospholipid 
metabolic pathways (Carman and Han, 2011; Chen et al., 2007; Henry et al., 
2012a). Coordinated expression of the genes involved in phospholipid synthesis 
highlights the importance of inositol metabolism in the regulation of membrane 
biogenesis.  
Inositol depletion is an outcome of treatment with mood-stabilizers lithium and 
valproate due to the inhibition of different steps in the biosynthesis of inositol 
(Allison et al., 1980; Hallcher and Sherman, 1980; Ju and Greenberg, 2003; 
Shaltiel et al., 2004a). To gain insight into mechanisms of inositol regulation, we 
carried out a targeted screen of yeast mutants carrying deletions in genes with 
possible roles in inositol metabolism to identify mutants that were sensitive to 
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valproate. One gene identified in this manner KCS1, encodes inositol 
pyrophosphate kinase, which catalyzes the synthesis of inositol pyrophosphates. 
This finding suggested that inositol pyrophosphates may function in the 
regulation of inositol metabolism.  
Inositol pyrophosphates are ubiquitous in mammalian and yeast cells (Barker et 
al.; Bennett et al.) and have diverse roles in stress response (Dubois et al., 
2002a), vesicle trafficking (Saiardi et al., 2002), vacuolar biogenesis (Dubois et 
al.), telomere maintenance (Saiardi et al., 2005), and energy dynamics 
(Szijgyarto et al., 2011b).  Naturally occurring inositol pyrophosphates are 
produced from two classes of evolutionarily conserved enzymes that utilize 
substrates inositol pentakisphosphate (IP5) or inositol hexakis-phosphate (IP6) 
(Barker et al.). As shown in Fig. 2-1 (see Abbreviations for inositol 
polyphosphates), Ipk2 and Ipk1 sequentially add a phosphate to distinct sites of 
the hydroxyl group of the inositol ring. Kcs1 (IP6K in mammals) catalyzes the 
addition of pyrophosphates to the 5-hydroxyl of IP5 and IP6, generating 5PP-IP4 
and 5PP-IP5 (5-IP7). Vip1 (PPIP5K or IP7K in mammals) catalyzes the addition of 
pyrophosphates to the 1-hydroxyl of IP6, generating 1-IP7 (Lin et al., 2009; 
Mulugu et al., 2007; Wang et al., 2012). In S. cerevisiae, Vip1-produced 1-IP7 is 
known to regulate phosphate homeostasis by disrupting the Pho80-Pho85-Pho81 
complex (Lee et al., 2007). In response to starvation for phosphates, increased 
1-IP7 causes inactivation of the kinase complex Pho80-Pho85 (Lee et al., 2007). 
This leads to activation of the transcription factor Pho4 (Komeili and O'Shea, 
1999) and upregulation of PHO5 and PHO84, which scavenge phosphates 
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(Carroll and O'Shea, 2002; Wykoff and O'Shea, 2001). Interestingly, recruitment 
of Ino80 to PHO5 and PHO84 promoters requires the production of IP4/IP5 by 
Ipk2 (Steger et al., 2003), suggesting that inositol polyphosphates play a role in 
Ino80-mediated chromatin remodeling.  
In the current study, we report that inositol pyrophosphates carry out a novel 
function in the regulation of inositol metabolism. To elucidate the mechanism 
whereby inositol pyrophosphates regulate inositol synthesis, as suggested by the 
kcs1Δ phenotype, we determined the effects of disruption of inositol 
pyrophosphate synthesis on inositol homeostasis. Our findings suggest that 
inositol pyrophosphates synthesized from IP5 by Kcs1 are required for the 
optimal transcription of INO1, but not for activity of the Opi1-Ino2-Ino4 regulatory 
complex. Moreover, the Kcs1 protein levels are dynamically altered by addition or 
removal of exogenous inositol, suggesting that rapid turnover of inositol 
pyrophosphates generated by Kcs1 regulates inositol synthesis. We propose a 





Figure 2-1: Biosynthetic pathway for inositol pyrophosphates in yeast. 
IP3 generated from hydrolysis of PIP2 by Plc1 is the precursor for the 
synthesis of inositol poly-/pyro- phosphates. Ipk2 catalyzes the synthesis of 
IP4 and IP5, and Ipk1 catalyzes the synthesis of IP6. Kcs1 can use IP5 or IP6 
as substrates. Kcs1 catalyzes the conversion of IP5 to 5PP-IP4 and further to 
(PP)2-IP3 (not shown), and the conversion of IP6 to 5-IP7. Vip1 catalyzes the 
synthesis of 1-IP7, and Kcs1 and Vip1 together catalyze the synthesis 1,5-IP8. 
The open circles indicate an axial hydroxyl groups that are not 
phosphorylated. The closed dark circles represent phosphate groups and the 
closed   grey   circles   β–phosphates.   Inositol polyphosphate nomenclature is 
described in a review article (Bennett et al., 2006b) and summarized in 
Abbreviations. 
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MATERIALS AND METHODS 
Yeast strains, plasmids and growth media 
The yeast S. cerevisiae strains used in this study are listed in Table 1-1. Wild 
type (WT) strain with the GFP-HIS3MX6 cassette integrated at the carboxy 
terminal end of the KCS1 open reading frame is obtained from the Yeast-GFP 
Clone Collection (Invitrogen). Single deletion mutants with the GFP tag and 
double mutants were obtained by tetrad dissection. Synthetic complete (SC) 
medium contained adenine (20.25 mg/liter), arginine (20 mg/liter), histidine (20 
mg/liter), leucine (60 mg/liter), lysine (200 mg/liter), methionine (20 mg/liter), 
threonine (300 mg/liter), tryptophan (20 mg/liter), uracil (20 mg/liter), yeast 
nitrogen base without amino acids (Difco), all the essential components of 
DIFCO vitamin (inositol-free), 0.2% ammonium sulfate, and glucose (2%). 
Inositol was supplemented separately where indicated. Synthetic dropout media 
contained all ingredients mentioned above except for the amino acid used as a 
selectable marker, and were used to culture strains containing a plasmid. 
Synthetic complete or dropout medium containing  75  μM  inositol  is  denoted  as  I+,  
while medium lacking inositol is denoted I-. 
The plasmids used in this study are listed in Table 1-2. The plasmids pFL38, 
pFV198, pFV217, and pFV241 (Dubois et al., 2002b)are gifts from Dr. Evelyne 
Dubois, and the UASINO reporter plasmid (Loewen et al., 2004) is a gift from Dr. 




Table 1-1 Strains used in this study  
   
BY4741 MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0 Invitrogen 
BY4742 MATα  his3Δ1  leu2Δ0  lys2Δ0  ura3Δ0 Invitrogen 
kcs1Δ MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  kcs1Δ::KanMX6 Invitrogen 
vip1Δ MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  vip1Δ::KanMX6 Invitrogen 
ipk1Δ MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  ipk1Δ::KanMX6 Invitrogen 
ipk2Δ MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0 ipk2Δ::KanMX6 This study 
opi1Δ MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  opi1Δ::KanMX6 Invitrogen 
kcs1Δvip1Δ 
MATα  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  kcs1Δ::KanMX6  
vip1Δ::KanMX6 this study 
kcs1Δopi1Δ 
MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  kcs1Δ::KanMX6  
opi1Δ::KanMX6 this study 
kcs1Δipk1Δ 
MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  kcs1Δ::KanMX6  
ipk1Δ::KanMX6 this study 
kcs1Δipk2Δ 
MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  kcs1Δ::KanMX6  
ipk2Δ::KanMX6 this study 
WT OPI1-
GFP 







MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  kcs1Δ::KanMX6  
OPi1-GFP-HIS3 Ste2pr-LEU2 this study 
WT KCS1-
GFP MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  KCS1-GFP-HIS3 Invitrogen 
opi1Δ  
KCS1-GFP 
MATα  his3Δ1  leu2Δ0  ura3Δ0  opi1Δ::KanMX6  KCS1-GFP-
HIS3 this study 
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Table 1-2 plasmids used in this study 
   
pTL416ILZ  UASINO reporter plasmid 
(Loewen et al., 
2004) 
pFL38 CEN, URA3 
(Dubois et al., 
2002b) 
pFV198 pFL38, KCS1L1L2→AA 
(Dubois et al., 
2002b) 
pFV217 pFL38, KCS1SLL→AAA 
(Dubois et al., 
2002b) 
pFV241 pFL38, KCS1 
(Dubois et al., 
2002b) 
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standard protocols. The plasmids were transformed into yeast strains using a 
one-step transformation protocol (Chen et al., 1992). 
 
Measurement of intracellular inositol 
Intracellular inositol was measured as described previously (Ju and Greenberg, 
2003) with minor modifications. Briefly, cells were harvested at 4°C by 
centrifugation, washed once with ice-cold water, and resuspended in ice-cold 7.5% 
perchloric acid. Each sample was lysed by vortexing with acid washed glass 
beads for 10 minutes at 30 second intervals, alternating with 30 seconds 
incubation on ice. Perchloric acid was removed by titration to pH 7.0 with ice-cold 
10 M potassium hydroxide. The cell extracts were clarified by centrifugation for 5 
min at 2000 g at 4°C. The supernatants were collected, and intracellular inositol 
was measured by enzyme-coupled fluorescence assay (Maslanski and Busa, 
1990). Inositol content (pmol) was normalized to units of A550. 
 
Determination of phosphatidylinositol (PI) by thin layer chromatography 
(TLC)  
Yeast cells were grown to the mid-logarithmic growth phases (A550 = 1.0) at 30°C. 
Cells were then washed once with ice-cold water, and total lipids were extracted 
with chloroform: methanol (2:1) (v/v) as described previously (Schneiter and 
Daum, 2006). The extracted lipids were applied onto silica gel plates (Partsil® 
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K6F 60 Å, Whatman) pre-treated with 1.8% boric acid and separated in the one-
dimension solvent system chloroform /triethylamine/ethanol/water (30:35:35:7) as 
described previously (Vaden et al., 2005). Phospholipids were visualized by 
carbonization at 120 °C for 10 min after dipping plates into 3.2% H2SO4 and 0.5% 
MnCl2 and subsequent staining with iodine vapor. Stained silica plates were 
quantified using ImageJ software (National Institutes of Health). Total PI levels in 




Cells were pre-cultured in I+ to the mid-logarithmic growth phase at 30°C, 
counted  using  a  hemocytometer,  and  washed  with  sterile  water.  3  μL  aliquots  of  
a series of 10-fold dilutions were spotted onto I+ or I- plates and incubated for 3 
days at the indicated temperatures.  
 
Real-Time quantitative PCR (RT-qPCR) analysis 
Cells were grown to the indicated growth phase and immediately harvested at 
4°C. Total RNA was extracted using hot phenol (Ausubel et al., 1994), and 
purified using the RNeasy Mini Plus kit (QIAGEN, Valencia, CA). Complementary 
DNA (cDNA) was synthesized using the First Strand cDNA synthesis Kit (Roche 
Applied  Science,  Indianapolis,  IN)  according  to  the  manufacturer’s  manuals.  RT-
qPCR  reactions  were  performed  in  a  20  μL  volume  using  Brilliant III Ultra-Faster 
SYBR Green QPCR Master Mix (Agilent Technologies, Santa Clara, CA).  
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Triplicates were included for each reaction. The primers for RT-qPCR are listed 
in Table 1-3. RNA levels were normalized to ACT1. Relative values of mRNA 
transcripts are shown as fold change relative to indicated controls. Primer sets 
were validated according to Methods and Applications Guide from Agilent 
Technologies. Optimal primer concentrations were determined, and primer 
specificity of a single product monitored by a melt curve following the 
amplification reaction. All the primers were validated by measurement of PCR 
reaction efficiency. All the primers used in this study have calculated reaction 
efficiency between 95-105%. 
 
Quantification of INO1 expression 
 
RT-qPCR analysis. Cells were pre-grown in I+ to the mid-logarithmic phase and 
inoculated into fresh I+ medium at A550 of 0.05. When the A550 reached 0.5, cells 
were harvested by centrifugation at 3500 rpm for 3 minutes at 30°C, washed with 
prewarmed I- or I+, and resuspended to fresh I- or I+, respectively. Samples 
were harvested for RT-qPCR analysis at the indicated times by centrifugation at 
3500 rpm for 3 min at 4°C. Cells grown in I+ to an A550 of 0.5 were collected at 
4°C and used as the 0 hour time point.  
 
β-galactosidase reporter assay. WT and mutant cells that were transformed 
with the UASINO reporter plasmid were precultured in I+ to the mid-logarithmic 




Table 1-3 Real-time PCR primers used in this study.  
   
Gene Primers Sequence (5' to 3') 
ACT1 Forward TCCGGTGATGGTGTTACTCA 
  Reverse GGCCAAATCGATTCTCAAAA 
INO1 Forward CAAGTCGGGACAAACCAAGT 
  Reverse ATAGGATGCAATGGAGACCG 
INO2 Forward TCATCAGCCTATCGGCAATGACCA 
  Reverse ATTTCCGTACCTTCACAGGGTCGT 
INO4 Forward AGCAGCGATCCCGTACAAGAACAA 
  Reverse GTCCATCACCCAGCTCCCAAATTA 
PDA1 Forward ATTGATGGGTAGAAGAGCCGGTGT 
  Reverse AGGCGTCCTCGTTCTTGTATTGGT 
RDN18 Forward CTTGTGCTGGCGATGGTTCATTCA 
  Reverse TCCTTGGATGTGGTAGCCGTTTCT 
TAF10 Forward GCAGCTATTGCAAGGACAGCAACA 
  Reverse AGCAACAGCGCTACTGAGATCGTT 
TDH3 Forward ACCACTGTCCACTCTTTGACTGCT 
  Reverse ACATCGACGGTTGGGACTCTGAAA 
TFC1 Forward AACTGCCGCCACCTCCTAAGTTAT 
  Reverse TCCCTTCACTTCTGTGACACCGTT 
UBC6 Forward AGCAGGCTCACAAGAGATTGACGA 
  Reverse TACCGTGATATTGACCGCCCTTGT 
SPT15 Forward CGCTACATGCCCGTAATGCAGAAT 
  Reverse TACTGGCCAGCTTTGAGTCATCCT 
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fresh I-.   After   continuous   growth   for   4   hours,   cells   were   harvested,   and   β-
galactosidase was assayed as described previously (Fu and Xiao, 2006; Loewen 
et al., 2004).  
 
SDS-PAGE and Western blot analysis 
 
Cells grown to the indicated growth phase were harvested at 4°C and subjected 
to mechanical breakage at 4°C with acid washed glass beads in lysis buffer 
containing 50 mM Tris, 125 mM sodium chloride, 1% NP-40, 2 mM EDTA, and 1x 
protease inhibitor cocktail (Roche). Protein extracts were clarified twice by 5 min-
centrifugation at 13,000 g at 4°C to remove cell debris and glass beads.  Protein 
concentration was determined using the BCATM protein assay (Pierce Protein), 
with bovine serum   albumin   as   the   standard.   Extracts   containing   50   μg   protein  
were boiled with protein gel sample buffer, separated on 8% SDS-PAGE, and 
electrotransferred to a polyvinylidene difluoride (PVDF) membrane (Millipore). 
The membrane was incubated with antibodies (1:3,000 anti-GFP; 1:3,000 anti-
tubulin; 1:5,000 appropriate secondary antibodies conjugated with HPR), and 
visualized   using   ECL   Plus   substrate   (Pierce   Protein),   with   α-tubulin as the 






Visualization of Opi1p-GFP using fluorescence microscopy 
 
To visualize the localization of Opi1p-GFP in WT and kcs1Δ cells, fluorescence 
microscopy was performed using an Olympus BX41 epi-fluorescence microscope. 
Images were acquired using an Olympus Q-Color3 digitally charge coupled 







Deletion of KCS1 results in decreased inositol biosynthesis. 
To identify potential regulators of inositol biosynthesis, we carried out a targeted 
screen for the growth of mutants hypersensitive to the inositol depleting drug 
valproate. Yeast mutants carrying deletions in genes with reported functions in 
inositol metabolism (Saccharomyces Genome Database (SGD)) were grown on 
I+ or I- plates. We screened 26 deletion mutants in categories expected to affect 
inositol metabolism, including inositol polyphosphate kinases, protein kinases 
and protein phosphatases, vacuolar proteins, and ER membrane proteins. 
Deletion mutants that exhibited defective growth on I- were further tested for 
growth on medium supplemented with valproate. One of the mutants identified in 
this screen was kcs1Δ. Inositol auxotrophy of kcs1Δ was also reported in 
genome-wide studies of inositol auxotrophy (Villa-García et al., 2011; Young et 
al., 2010). To further investigate the role of KCS1 in the regulation of inositol 
metabolism, we analyzed the growth of the kcs1Δ mutant. As seen in Fig. 2-2A, 
kcs1Δ   cells showed an extended lag phase when inoculated into I+ medium 
compared to isogenic WT cells. Importantly, they did not significantly grow in I- 
medium. Furthermore, growth of the mutant was diminished relative to that of WT 
cells at elevated temperatures, even in the presence of inositol (Fig. 2-2B). 
Consistent with inositol auxotrophy, intracellular inositol levels in kcs1Δ were 
reduced to less than 30% of WT levels (Fig. 2-2C), and PI were about 42% of  
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Figure 2-2: Decreased inositol biosynthesis in kcs1Δ is due to 
downregulation of INO1 transcription. (A) Growth curves for WT and isogenic 
kcs1Δ,  vip1Δ, and kcs1Δvip1Δ cells grown in I+ and I-. Cells were inoculated in 
I+ or I- at initial A550 of 0.05, and A550 was measured at indicated times. The 




Figure 2-2 (continued): (B) Serial ten-fold dilutions of WT and kcs1Δ cells were 
spotted on synthetic complete medium without or with supplementation of 
inositol. Plates were incubated at indicated temperatures for 3 days. The figure 
shows a representative experiment that has been reproduced three times. (C) 
Cells were grown   in   synthetic   complete  medium   containing   5   μM   inositol   and  
harvested in the logarithmic phase (A550 ≤  1.0)  or   the  stationary  phase   (A550 ≥  
2.0).   Intracellular   inositol   was   measured   as   described   under   “Experimental  
Procedures.”   The   average   values   and   standard deviation of at least three 
independent experiments are shown. (D) PI levels were assayed using the TLC 
method   described   under   “Experimental   procedures”.   Cells   were   grown   and  
harvested at the logarithmic phase in the same condition as for intracelluar 
inositol assay. The figure is representative of two independent experiments. (E) 
INO1 expression in WT and kcs1Δ cells was determined using RT-qPCR as 
described   under   “Experimental   Procedures”.   Cell   pellets   were   collected   for  
assaying before (0 hour) and after (0.5, 1, and 2 hours) removal of inositol. 
Values were normalized to the internal control ACT1. INO1 transcripts 
normalized to ACT1 are represented as fold change relative to WT INO1 levels 
at 0 hour. (F) Transcripts of PDA1, RDN18, TAF10, TDH3, TFC1, UBC6, and 
SPT15 and INO1 were assayed by RT-qPCR in WT and kcs1Δ cells 2 hours 
after removal of inositol. The values of gene transcription in WT normalized to 
ACT1 are represented as fold change relative to the values in kcs1Δ. ACT1 is 
used as the internal control. The data shown in (E) and (F) are the average of at 
least three experiments + standard deviation. 
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WT (Fig. 2-2D). Inositol biosynthesis is activated in WT cells in inositol-deficient 
medium by dramatically upregulating INO1 transcription (Henry et al., 2012a). 
However, upregulation of INO1 mRNA was not observed in kcs1Δ   (Fig. 2-2E), 
suggesting that transcription of INO1 is defective in the mutant. We addressed 
the possibility that defective INO1 transcription resulted from a global repression 
of transcription by comparing mRNA expression of a variety of genes in WT and 
kcs1Δ,   including genes in glycolysis (PDA1, TDH3), basal transcription (TAF10, 
TFC1, SPT15), and protein processing (RDN18, UBC6). None of these genes 
exhibited decreased expression in kcs1Δ (Fig. 2-2F). Taken together, these 
studies suggested that decreased INO1 transcription in kcs1Δ diminishes 
biosynthesis of inositol and PI, leading to inositol auxotrophy. 
Decreased  inositol  biosynthesis  in  kcs1Δ  is  not  due  to  perturbation  of  the  UASINO 
regulatory complex Opi1-Ino2-Ino4. 
The native promoter of INO1 contains the UASINO element that is widely found in 
the promoter regions of many genes, including genes involved in phospholipid 
metabolism (Bachhawat et al., 1995b). As shown in Fig. 2-3A, transcription of 
genes containing the UASINO element is activated by the Ino2-Ino4 heterodimer 
interacting with the UASINO-containing promoter, and repressed by the interaction 
of Opi1 with Ino2 (Ambroziak and Henry, 1994; Bachhawat et al., 1995a; Henry 
et al., 2012a; Schwank et al., 1995). Among genes regulated in this manner, 
INO1 is the most responsive (Henry et al., 2012a; Loewen, 2012). In the absence 
of inositol, localization of Opi1 on the ER is stabilized by interaction with Scs2 
and PA (Loewen et al., 2004). In response to exogenous inositol, Opi1 is  
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Figure 2-3: Opi1-Ino2-Ino4 is not perturbed in kcs1Δ. (A) The regulatory 
mechanism of INO1 transcription. Ino2 and Ino4 are activators of INO1 
transcription. Scs2 stabilizes the negative regulator Opi1 on the ER membrane 
with phosphatidic acid (PA). Upon addition of inositol, synthesis of 
phosphatidylinositol (PI) rapidly consumes PA, releasing Opi1p, which 
translocates to the nucleus and represses INO1 expression. (B) WT or kcs1Δ 
cells with GFP-tagged Opi1 were cultured in I+ to the mid-logarithmic phase 
(A550 of 0.5), washed with pre-warmed I-, and resuspended in prewarmed and 
fresh I-. After growing for 2 hours in I-, cells were examined under a 
fluorescence microscope. To compare the localization of Opi1-GFP on the 
periphery  of  the  nucleus  and  in  the  nucleus,  75  μM  inositol  was  added  to  WT  or  
kcs1Δ cells in I-. After addition of inositol for 5 minutes, cells were observed 
under the fluorescence microscope. The figure is representative of six 
independent experiments. (C) INO2 and (D) INO4 transcripts were assayed in 
WT and kcs1Δ cells cultured in the conditions described in Fig. 2E. The data 
shown in (C) and (D) are the average of three experiments + standard deviation. 
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translocated to the nucleus, inhibiting INO1 transcription (Carman and Henry, 
2007a; Loewen et al., 2004). We addressed the possibility that decreased 
transcription of INO1 in kcs1Δ   is caused by retention of the transcription 
repressor Opi1 in the nucleus. As shown in Fig. 2-3B, in I- conditions, GFP-
tagged Opi1 locates on the nuclear rim in kcs1Δ as observed in WT cells, 
indicating that the translocation of Opi1 is not perturbed in kcs1Δ.   Therefore, 
KCS1 does not regulate INO1 transcription by affecting the localization of Opi1.  
We further investigated if the INO1 transcription defect in kcs1Δ was caused by 
perturbation of the transcriptional activators Ino2 and Ino4. INO2 is known to be 
upregulated in I-, while INO4 is constitutively expressed in both I+ and I- 
(Ashburner and Lopes, 1995). While INO2 transcripts were decreased in kcs1Δ 
relative to WT cells, expression in I- was greater than in I+ in both strains (Fig. 2-
3C), indicating that decreased INO1 expression in kcs1Δ is not due to an inability 
to upregulate INO2.  Levels of the constitutively expressed INO4 were not 
significantly diminished in kcs1Δ (Fig. 2-3D). These experiments suggest that 
decreased transcription of INO1 in kcs1Δ is most likely not due to decreased 
availability of Ino2 and Ino4, although levels of INO2 transcription were 
somewhat decreased relative to WT. 
KCS1 is required for optimal INO1 transcription. 
As mentioned, OPI1 is a transcriptional repressor of INO1, and deletion of OPI1 
leads to overproduction of inositol (Greenberg et al., 1982). Not surprisingly, 










Figure 2-4: 5PP-IP4 is indispensible for optimal INO1 transcription. (A) 
Serial ten-fold dilutions of WT, kcs1Δ,  opi1Δ,   kcs1Δopi1Δ,   ipk1Δ,   kcs1Δipk1Δ,  
ipk2Δ,   kcs1Δipk2Δ,   vip1Δ,   and kcs1Δvip1Δ   cells were spotted on I- and I+ 
plates, which were incubated at 30°C or 37°C for 3 days. The figure shown is 
representative of three experiments. (B) WT and isogenic mutants were 
transformed with a UASINO-lacZ reporter plasmid. Cells were precultured in I+ to 
the mid-logarithmic phase (A550 of 0.5-0.8), then pelleted, washed with 
prewarmed I-, and resuspended in prewarmed and fresh I-. After the shift, cells 
were continuously   cultured   for  4  hours.  β-galactosidase activity was measured 
as  described  under   “Experimental  Procedures.”  The  data  shown   in   (B)  are   the  





Interestingly, deletion of OPI1 also alleviated the growth defect of kcs1Δ on I+ at 
30°C (Fig. 2-4A), suggesting that the Opi1-controlled repression of other genes 
may also be deleterious to the growth of kcs1Δ. Deletion of OPI1 in kcs1Δ  
restored PI levels (Fig. 2-2D). Relatively higher PI levels in opi1Δ than WT were 
most likely due to overproduction of inositol in opi1Δ. To determine if INO1 
transcription is also restored in kcs1Δopi1Δ, we analyzed INO1 expression in the 
double deletion mutant transformed with the INO1-lacZ reporter. Surprisingly, 
although deletion of OPI1 increased INO1-lacZ expression in kcs1Δ, expression 
in kcs1Δopi1Δ was only 20-30% of that in WT and opi1Δ cells (Fig. 2-4B), 
suggesting that KCS1 is required for optimal INO1 transcription.  
Both bZIP and DINS domains of Kcs1 are required for INO1 transcription. 
As depicted in Fig. 2-5A, Kcs1 has two functional domains (Huang and 
Symington, 1995; Saiardi et al., 2000): the kinase domain (also referred to 
diphosphoinositol polyphosphate synthase, DINS) (Saiardi et al., 2000; Saiardi et 
al., 1999) and two bZIP domains containing four leucine heptad repeats (Dubois 
et al., 2002a; Huang and Symington, 1995). Plasmids containing the full length 
KCS1 or KCS1 with site mutations in each functional domain were constructed 
and characterized previously (Dubois et al., 2002a) (Fig. 2-5A). To determine if 
these domains are required for INO1 transcription, we assayed growth and INO1 
expression in kcs1Δ cells transformed with these plasmids. In contrast to the full 
length KCS1 (pKCS1), the kinase-mutated KCS1 (pKCS1SLL→AAA) did not rescue 
inositol auxotrophy or restore INO1 transcription in kcs1Δ  (Fig. 2-5B and 2-5C). It 









Figure 2-5: Basic leucine zipper (bZIP) and inositol pyrophosphate kinase 
(DINS) domains of Kcs1 are required for INO1 transcription. (A) Diagram of 
the bZIP and the DINS functional domains of Kcs1 indicating site mutations 
disrupting individual domains. (B) Serial ten-fold dilutions of kcs1Δ cells carrying 
either empty vector (pURA3), mutated bZIP domain (pkcs1 ), mutated 
DINS domain (pkcs1 ), or WT KCS1 were spotted on I- or I+ plates. 
Plates were incubated at 30°C for 3 days. The figure shown is representative of 
three experiments.  (C) Cells harboring the empty vector (pEV), WT KCS1, or 
mutated KCS1 were cultured in I+ to the mid-logarithmic phase (A550 of 0.5), 
pelleted, washed with prewarmed I+ or I-, and resuspended in fresh prewarmed 
I+ or I-. After the shift, cells were grown for 2 hours. INO1 mRNA was quantified 
using RT-qPCR  as  described  in  “Experimental  Procedures.”  The  data  shown  in  
(C) are the average of three experiments + standard deviation. 
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5PP-IP4 is virtually eliminated by mutation of the kinase domain (Dubois et al., 
2002a). Therefore, Kcs1 kinase activity, which catalyzes the synthesis of inositol 
pyrophosphates, is required for inositol biosynthesis as well as optimal INO1 
transcription. Previous studies also indicated that site mutations in the bZIP 
domain did not affect the generation of inositol pyrophosphates (Dubois et al., 
2002a). Unexpectedly, kcs1Δ  cells containing the bZIP-mutated KCS1 exhibited 
decreased growth on I-, which was rescued by inositol (Fig. 2-5B). Consistent 
with the defective growth on I-, the strain also exhibited a 50% decrease in INO1 
expression compared to WT (Fig. 2-5C). Therefore, both the bZIP and the kinase 
domains of Kcs1 are required for INO1 transcription. 
Kcs1 protein modulates INO1 transcription. 
To gain insight into how KCS1 modulates INO1 transcription, we measured 
protein levels of GFP-tagged Kcs1 in WT and opi1Δ cells that were grown in I+ or 
I-. Two bands were detected by anti-GFP, most likely corresponding to full-length 
and truncated Kcs1 proteins, as reported previously (Nishizawa et al., 2008). WT 
cells cultured in I- (Fig. 2-6A), conditions in which INO1 transcription is increased, 
exhibited elevated levels of Kcs1 protein compared to WT cells cultured in I+. In 
addition, both Kcs1 protein and INO1 transcription levels were decreased at 
elevated  temperature  compared  to  those  observed  at  30˚C  (Figs.  2-6A and 2-6B). 
Interestingly, decreased Kcs1 protein levels in I+ relative to I- were not observed 
in opi1Δ cells (Fig. 2-6A), indicating that OPI1 is required to regulate Kcs1 protein 
in response to inositol.  
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Figure 2-6: Increased Kcs1 protein levels in I- conditions. (A) Cell lysates 
were prepared from WT or isogenic opi1Δ cells containing GFP-tagged Kcs1. 
Cells were cultured in I+ or I- to the mid-logarithmic phase (A550 of 0.5) at 30°C 
or 37°C as indicated. Anti-GFP antibody was used to detect Kcs1-GFP protein 
levels   using  Western  blot  analysis.   50  μg  of   total   protein  was loaded for each 
sample,  and  α-tubulin was used as an internal control. The levels of full-length 
Kcs1 protein (upper band) were quantified using ImageJ software (lower panel). 
The figure shown is representative of three experiments. (B) INO1 derepression 
at higher temperature was measured in WT cells transformed with the UASINO-
lacZ reporter plasmid. Cells were precultured in I+ at 30°C or 37°C to the mid-
logarithmic phase (A550 of 0.5-0.8), then pelleted, washed with I- that was 
prewarmed to 30°C or 37°C, and resuspended in prewarmed and fresh I-. After 
the   shift,   cells   were   continuously   cultured   at   30°C   or   37°C   for   4   hours.   β-
galactosidase   activity   was   measured   as   described   under   “Experimental  




In order to determine if Kcs1 protein levels respond specifically to inositol, we 
observed the effects on Kcs1 protein of shifting cells from I+ to fresh I- medium 
conditions that increase INO1 expression. WT cells were grown in I+ to the mid-
logarithmic phase (A550 of 0.5), then shifted to prewarmed I+ or I- medium, and 
harvested for analysis of Kcs1 protein levels and INO1 expression. As shown in 
Fig. 2-7A, by 2 hours after the shift to I-, levels of the full length Kcs1 protein 
increased more than 10-fold. Levels decrease after 4 hours, and Kcs1 was not 
detected at 6 hours. This pattern is consistent with the pattern of INO1 
expression (Fig. 2-7B), which peaked at 2 hours and was significantly diminished 
at 6 hours. Kcs1 protein was not increased significantly in cells shifted to fresh I+ 
medium (Fig. 2-7A). These findings indicated that Kcs1 protein levels and INO1 
transcription levels are regulated similarly in WT cells in response to exogenous 
inositol. In contrast to WT cells, opi1Δ cells did not exhibit an increase in Kcs1 
protein in response to inositol (Fig. 2-7A), indicating that Opi1 regulates Kcs1 
protein levels. Interestingly, in spite of the dramatic increase in Kcs1 protein in 
response to the shift from I+ to I-, transcription of KCS1 was not altered (Fig. 2-
7C).  
In reciprocal experiments, we assayed Kcs1 protein levels in cells shifted from I- 
to I+ (Fig. 2-7D). WT cells were precultured in I- to the mid-logarithmic phase 
(A550 of 0.5), inositol was then added, and cells were harvested for analysis of 
Kcs1 protein levels at the indicated times. In control cells (I-), Kcs1 protein 
exhibited a steady decrease after 1 hour and was reduced to less than 10% of 
the initial level within 4 hours. In cells supplemented with inositol, the decrease in  
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Figure 2-7: Kcs1 protein levels in response to exogenous inositol. (A) WT 
and isogenic opi1Δ cells were precultured in I+ to the mid-logarithmic phase 
(A550 of 0.5), washed with prewarmed I+ or I-, and resuspended in prewarmed I+ 
or I- medium. Cells were grown for the indicated times, and Kcs1-GFP protein 
levels were assayed as described in Fig. 6. Kcs1-GFP levels are normalized to 
the level of each individual strain at time 0. The figure shown is representative of 
two independent experiments. (B) INO1 and (C) KCS1 transcription levels in 
response to the same shift to I+ or I- were assayed using RT-qPCR as described 
under   “Experimental   Procedures”.   The   data   shown   in   (B)   and   (C)   are   the  
average of three experiments + standard deviation. (D) WT cells were 
precultured in I- to the mid-logarithmic phase (A550 of 0.5), and inositol was 
added as indicated. Growth curves are depicted in the upper panel. Cells were 
grown for the indicated times, and Kcs1-GFP protein levels were assayed as 
described in Fig. 6 and shown in the lower panel. The figure shown is 
representative of three experiments. 
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Kcs1 protein levels was greater than in I- controls. The decrease in Kcs1 protein 
is consistent with the well-established rapid decrease in INO1 transcription 
observed in response to inositol (Gaspar et al., 2006a; Loewen et al., 2004). 
Taken together, these experiments indicate that Kcs1 protein, but not the 
transcription of KCS1, is regulated in response to exogenous inositol, and this 
modulation of Kcs1 protein requires Opi1. 
Inositol pyrophosphates 5PP-IP4 synthesized from IP5 by Kcs1 are required for 
INO1 transcription. 
The findings that Kcs1 protein is required for INO1 expression and that levels of 
INO1 transcription correspond to levels of Kcs1 protein suggest that Kcs1-
catalyzed synthesis of inositol pyrophosphates regulates INO1 expression. We 
analyzed well-characterized inositol pyro-phosphate mutants to determine which 
inositol pyrophosphates are responsible for the regulation of INO1 transcription. 
The biosynthetic pathways for generating soluble inositol polyphosphates are 
depicted in Fig. 2-1. Hydrolysis of PIP2 by Plc1 provides IP3 as a precursor for 
the synthesis of inositol polyphosphates. Ipk2 catalyzes the synthesis of IP4 and 
IP5, and Ipk1 catalyzes the synthesis of IP6. Kcs1 catalyzes the 
pyrophosphorylation of IP5 to 5PP-IP4 and further to (PP)2-IP3 (not shown), and 
IP6 to 5-IP7. (Draskovic et al., 2008; Onnebo and Saiardi, 2009; Saiardi et al., 
1999). Vip1 catalyzes the synthesis of inositol pyrophosphates at the 1- hydroxyl 
site of the inositol ring (Lin et al., 2009; Mulugu et al., 2007; Wang et al., 2012). 
To assess which inositol poly- and/or pyro- phosphates are involved in the 
regulation of inositol biosynthesis, we assayed inositol auxotrophy and INO1 
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expression in all the single and double mutants shown in Table. 1-4. Inositol poly-
/pyro-phosphates synthesized by the WT and deletion strains shown in Table 1-4 
have been characterized previously by high performance liquid chromatography 
(HPLC) (Dubois et al., 2002a; Onnebo and Saiardi, 2009; Saiardi et al., 2002; 
York et al., 2005). As seen in Figs. 2-4A and 2-4B, ipk1Δ did not exhibit growth 
defects on I- plates, while deletion of KCS1 and/or IPK2 caused inositol 
auxotrophy consistent with severe defects in INO1-lacZ expression. Deletion of 
KCS1 in ipk1Δ, which additionally depletes inositol pyrophosphates synthesized 
from IP5, led to inositol auxotrophy. Consistent with this, INO1-lacZ expression 
was greatly reduced in kcs1Δipk1Δ compared to both WT and ipk1Δ. These 
findings suggest that Kcs1-generated 5PP-IP4 is required for optimal inositol 
biosynthesis. 
Inositol defects resulted from deletion of VIP1 were less severe than defects 
observed in kcs1Δ. Intracellular inositol was decreased by 20% in vip1Δ but 70% 
in kcs1Δ compared to WT (Fig. 2-2C), and INO1-lacZ expression was decreased 
about 50% in vip1Δ but almost not detected in kcs1Δ (Fig. 2-4B). The severe 
inositol defects in kcs1Δ, but not in vip1Δ, led to inositol auxotrophy. The double 
mutant kcs1Δvip1Δ has severe inositol defects as an inositol auxotroph. It 
exhibited a 60-80% decrease in intracellular inositol (Fig. 2-2C) and greatly 
decreased INO1-lacZ expression (Fig. 2-4B). Therefore, we conclude that kcs1Δ  









This is the first demonstration that Kcs1, which catalyzes the synthesis of inositol 
pyrophosphates, regulates inositol biosynthesis by controlling INO1 expression. 
We report that: 1) kcs1Δ   cells exhibit reduced intracellular inositol and PI, 
decreased INO1 expression, and decreased growth on inositol-free media; 2) 
disruption of either functional domain of Kcs1 protein causes inositol deficiency; 3) 
Kcs1 protein, but not transcription, is regulated in response to inositol; and 4) 
deletion of KCS1, but not IPK1, causes inositol deficiency, suggesting that 
synthesis of inositol pyrophosphates from IP5 but not IP6 is necessary for inositol 
synthesis. Based on these findings, we propose a model in which Kcs1-catalyzed 
synthesis of inositol pyrophosphates modulates INO1 transcription. 
Inositol pyrophosphate deficient kcs1Δ   cells exhibited defective inositol 
metabolism. Deletion of KCS1 led to an extended lag phase and nearly no 
growth in I- (Fig. 2-2A). Consistent with this, intracelluar inositol in kcs1Δ  cells 
was decreased to less than 30% of WT (Fig. 2-2C), while PI was decreased to 
about 42% of WT. In response to inositol depletion, kcs1Δ   cells displayed 
severely reduced INO1 derepression compared to WT cells (Fig. 2-2E). We 
conclude that the inositol defects in kcs1Δ are caused by defective INO1 
transcription. 
Disruption of either of the two functional domains DINS/kinase and bZIP of Kcs1 
resulted in defective inositol biosynthesis (Fig. 2-5). Although site mutations in 
either domain resulted in defective INO1 expression and inositol auxotrophy, the 
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mutated bZIP domain led to relatively mild defects in INO1 transcription 
compared to the mutated kinase domain (Fig. 2-5C). Disruption of the bZIP 
domain in KCS1 does not reduce the production of inositol pyrophosphates 
(Dubois et al., 2002a). Interestingly, the bZIP domain of KCS1 shares homology 
with the bZIP domain of Opi1 (White et al., 1991), as seen in the sequence 
alignment (Fig. 2-8A). The role of the bZIP domain has not been characterized in 
either protein. We speculate that the bZIP domain of Opi1 and Kcs1 may share 
binding sites, and that INO1 transcription may be regulated by the bZIP domains 
which mediate spatial localization of the proteins to the vicinity of the 
chromosomal regions where INO1 is located.  
Our findings indicate that Kcs1 protein, but not transcription, is regulated in 
response to inositol. A novel mechanism underlying the regulation of KCS1 
transcription in response to phosphate signals was identified previously 
(Nishizawa et al., 2008). Pho4-mediated transcription of the antisense and 
intragenic RNAs in KCS1 leads to the production of truncated Kcs1 protein and 
down-regulation of Kcs1 kinase activity (Nishizawa et al., 2008). This mechanism 
of regulation of phosphate signaling involves a positive feedback loop, in which 
species of the mRNAs and proteins of KCS1 are regulated by transcription of the 
antisense and intragenic RNAs. In contrast to Pho4-mediated regulation of KCS1, 
the KCS1 mRNA levels did not change in response to inositol (Fig. 2-7C), and 
the full length and truncated Kcs1 proteins were similarly increased in I- (Fig. 2-
7A) and decreased in I+ (Fig. 2-7D). These findings suggest a different 
mechanism underlying regulation of Kcs1 protein in inositol biosynthesis 
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compared to phosphate signaling. We speculate that Kcs1 protein may be 
controlled by translation or posttranslational modification, and/or stability of Kcs1 
protein.  
Analysis of inositol pyrophosphate mutants indicates that inositol pyrophosphates 
synthesized from IP5 but not IP6 are the most likely regulators of inositol 
biosynthesis. As summarized in Table 1-4, ipk1Δ, which lacks IP6 and IP7, did not 
exhibit inositol defects, while kcs1Δipk1Δ,   which lacks 5PP-IP4, IP6 and IP7, 
exhibited severe inositol defects. These findings suggest that 5PP-IP4, 
synthesized from IP5, is required for inositol biosynthesis. However, we cannot 
completely rule out the possibility that 5-IP7 is required for inositol biosynthesis. 
Indeed, deletion of ipk1Δ  caused only about a 30% decrease in INO1 expression 
(Fig. 2-4B), consistent with the findings of Wu and co-workers (Shen et al., 2003). 
Therefore, 5PP-IP4 is sufficient for inositol regulation, but IP7 also contributes to 
regulation. This is consistent with the moderate inositol defects observed in vip1Δ. 
Due to the difficulty of constructing a strain that can generate 5PP-IP4 and IP6, 
but not IP7, it is difficult to elucidate the specific role of IP7 in regulating INO1 
transcription.  
Interestingly, deletion of PLC1, the gene encoding phospholipase C that 
hydrolyses PIP2 and generates IP3 as precursors for inositol poly-/pyro- 
phosphates, exhibited elevated INO1 expression (Demczuk et al., 2008; 
Rupwate et al., 2012). It is likely that regulation of INO1 gene expression and 
inositol biosynthesis is coordinated with PLC activation in addition to the negative 
feedback curcuit in response to exogenous inositol. However, deletion of PLC1 is 
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lethal in some genetic backgrounds (Yoko-o et al., 1993). This complicates our 
understanding of the regulation of INO1 expression by PLC1. Interestingly, 
inositol polyphosphates IP5 and IP6, produced from phosphorylation of IP3 have 
roles in Ino80-mediated chromatin remodeling, a process also required for INO1 
expression (Shen et al., 2003; Steger et al., 2003). Regulation of INO1 
expression by synthesis of inositol pyrophosphates from IP5 and IP6 will further 
complicate the regulation of INO1 expression as altered levels of IP5 and IP6 may 
affect chromatin structure. We propose a model, depicted in Fig. 2-8, in which 
optimal INO1 transcription is modulated by the synthesis of inositol 
pyrophosphate, 5PP-IP4 (derived from IP5). Under derepressing conditions (I-), 
Opi1 is excluded from the nucleus (Henry et al., 2012a; Loewen et al., 2004), 
while Kcs1 protein levels are increased (Fig. 2-7A). Increased Kcs1 protein 
accelerates production of 5PP-IP4, which is required for optimal INO1 expression. 
Nuclear Opi1 most likely decreases Kcs1 protein as increased Kcs1 was 
observed in opi1Δ and in I- (during which Opi1 is excluded from the nucleus). 
Consistent with this, under repressing conditions (I+), Kcs1 is rapidly decreased 
(Fig. 2-7D), most likely due to Opi1 translocation into the nucleus where it 
represses INO1 expression (Henry et al., 2012a; Loewen et al., 2004) and 
decreases Kcs1 protein. Kcs1 and Opi1 may compete for a common binding site 
via the bZIP domain in the nucleus. Therefore, Opi1-dependent modulation of 
Kcs1 protein allows one or the other to interact with the common sites of specific 
nuclear proteins required for INO1 transcription in the nucleus, leading to 
repression or transcription of INO1, respectively. In this scenario, Kcs1 protein  
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Figure 2-8: Model of regulation of INO1 transcription by Kcs1 and inositol 
pyrophosphates. (A) Alignment of the bZIP domains in Opi1 and Kcs1. (B) 
Model depicting regulation of INO1 transcription by modulation of Kcs1 protein. 
Under derepressing conditions (I-, left panel), Opi1 is excluded from the nucleus. 
Increased Kcs1 protein facilitates synthesis of 5PP-IP5 from IP5, leading to 
optimal transcription of INO1. Under repressing conditions (I+, right panel), Opi1 







levels control INO1 transcription by regulating the synthesis of inositol 
pyrophosphates. We speculate that 5PP-IP4 may be required to recruit 
transcriptional activators to the INO1 promoter region or stabilize the interaction 
among those activators.   
In conclusion, we identified a novel mechanism whereby inositol biosynthesis is 
regulated by modulation of Kcs1 protein and suggested a model in which Kcs1-





DELETION OF THE CARDIOLIPIN-SPECIFIC PHOSPHOLIPASE CLD1 
RESCUES GROWTH AND LIFESPAN DEFECTS IN THE TAFAZZIN MUTANT: 
IMPLICATIONS FOR BARTH SYNDROME 
The work described in this chapter has been published in the Journal of 
Biological Chemistry 289: 3114-3125, 2014. 
 
INTRODUCTION 
Cardiolipin (CL) is a unique phospholipid that is predominant in mitochondrial 
membranes (Hostetler et al., 1972; Joshi et al., 2009). Unlike other membrane 
phospholipids, it contains two phosphatidyl moieties, four acyl chains and two 
negative charges (Lecocq and Ballou, 1964; Pangborn, 1947). As the signature 
lipid of mitochondria, it comprises about 15% of total mitochondrial phospholipids 
(Jakovcic et al., 1971) and interacts with a wide range of mitochondrial proteins 
(Claypool, 2009; Klingenberg, 2009; Schlame and Ren, 2009; Schlame et al., 
2000), including the ADP/ATP carrier (Beyer and Klingenberg, 1985; Claypool et 
al., 2008b) and respiratory complexes (Eble et al., 1990; Lange et al., 2001; 
Palsdottir et al., 2003; Shinzawa-Itoh et al., 2007). CL-protein interactions 
stabilize respiratory chain supercomplexes (Pfeiffer et al., 2003; Zhang et al., 
2002) and promote supramolecular associations between the ADP/ATP carrier 
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and respiratory supercomplexes (Claypool et al., 2008b). Therefore, it is not 
surprising that mitochondrial respiration and energy production are highly 
correlated with CL biosynthesis (Claypool et al., 2008b; Gohil et al., 2004; Jiang 
et al., 2000). Interestingly, CL deficiency also leads to deficiencies in diverse 
cellular functions other than mitochondrial bioenergetics, including mitochondrial 
dynamics (DeVay et al., 2009; Joshi et al., 2012), mitochondrial protein import 
(Gebert et al., 2009; Jiang et al., 2000), cell wall biogenesis (Zhong et al., 2005; 
Zhong et al., 2007), vacuolar function and morphology (Chen et al., 2008), cell 
cycle (Chen et al., 2010), aging (Zhou et al., 2009), and apoptosis (Gonzalvez 
and Gottlieb, 2007; Houtkooper and Vaz, 2008; Schug and Gottlieb, 2009). As 
CL is engaged in a plethora of cellular activities, the regulation of CL synthesis is 
crucially important. 
The synthesis of CL is well-characterized in Saccharomyces cerevisiae. As seen 
in Fig.3-1, Pgs1 catalyzes the committed step of CL synthesis by converting 
CDP-DAG and glyerol-3-phosphate to phosphatidylglycerolphosphate (PGP) 
(Chang et al., 1998a), which is dephosphorylated to phosphatidylglycerol (PG) by 
the PGP phosphatase Gep4 (Kelly and Greenberg, 1990; Osman et al., 2010). 
CL synthase (Crd1) catalyzes the f inal step of de novo CL synthesis by 
condensing PG and CDP-DAG to form CL with primarily saturated acyl chains 
(Chang et al., 1998b; Jiang et al., 1997; Tamai and Greenberg, 1990; Tuller et al., 






Figure 3-1: CL de novo synthesis and remodeling in S. cerevisiae. Pgs1 
catalyzes the committed step of CL synthesis by converting CDP-DAG to 
phosphatidylglycerolphosphate (PGP), which is dephosphorylated to 
phosphatidylglycerol (PG) by the GEP4-encoded PGP phosphatase. CL 
synthase, encoded by CRD1, condenses PG and CDP-DAG to form CL. CL 
synthesized de novo has primarily saturated acyl chains (CLsat). CLsat is 
deacylated by the CL-specific phospholipase Cld1 to monolysocardiolipin 
(MLCL), which is reacylated by tafazzin (the TAZ1 gene product) to CL 





mitochondrial membrane, CL undergoes remodeling in which acyl chains are 
exchanged. In this process, CL is deacylated to monolysocardiolipin (MLCL) by 
the CL-specific lipase Cld1 on the matrix side of the inner mitochondrial 
membrane (Baile et al., 2013; Beranek et al., 2009). MLCL is reacylated by the 
transacylase Taz1 in the mitochondrial periphery (Brandner et al., 2005; Claypool 
et al., 2008a; Gu et al., 2004; Testet et al., 2005). Remodeled CL has more 
unsaturated acyl chains than CL synthesized de novo (Beranek et al., 2009; Gu 
et al., 2004; Vaz et al., 2003; Xu et al., 2003). Although the CL remodeling genes 
and enzymes have been identified in yeast, the function of CL remodeling and 
mechanisms underlying its regulation are not understood. 
 
The importance of CL remodeling is underscored by the X-linked mitochondrial 
disorder Barth syndrome (BTHS), a cardioskeletal myopathy that results from 
mutations in the tafazzin gene (the homologue of yeast TAZ1) (Barth et al., 1983; 
Barth et al., 2004; Barth et al., 1999). Tafazzin deficiency leads to a decrease in 
the CL/MLCL ratio and a decrease in CL species containing unsaturated fatty 
acids (Acehan et al., 2011; Gu et al., 2004; Houtkooper et al., 2009; Schlame et 
al., 2003; Valianpour et al., 2002; Vreken et al., 2000; Xu et al., 2006). Which of 
these biochemical outcomes leads to the pathology in BTHS is not understood. 
Genetic inactivation of the CL-specific phospholipase iPLA2-GVIA rescued 
sterility defects associated with tafazzin deficiency in Drosophila (Malhotra et al., 
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2009). The mechanism underlying this rescue is not known. In mammals, CL-
specific phospholipases have not been identified, and multiple phospholipases 
supposedly catalyze the deacylation of CL (Hsu et al., 2013), complicating 
experiments to elucidate the role of deacylation in mammalian cells. In contrast, 
CLD1 is the only CL-specific phospholipase in S. cerevisiae (Beranek et al., 
2009).  The yeast cld1Δ mutant has decreased unsaturated CL compared to wild 
type cells, but the CL/MLCL ratio is not altered. In this study, we demonstrated 
for the first time that deletion of CLD1 rescued both respiratory and fermentative 
growth defects as well as decreased chronological life span in yeast taz1Δ cells. 
This suggests that deacylation of CL in the absence of tafazzin is deleterious 
because it leads to a decrease in the CL/MLCL ratio.  These findings argue 
against the current thought that defects in tafazzin deficient cells result from 
decreased unsaturated CL.  We further show that expression of CLD1 is 
regulated in response to conditions affecting mitochondrial respiration and 
controlled by the HAP transcriptional activator. Overexpression of CLD1 leads to 
decreased ATP production from mitochondrial respiration that is compensated by 
increased glycolysis. Based on these findings, we proposed that transcriptional 
regulation of CLD1 controls deacylation of CL, and the regulation of this process 
modulates cellular energy production 
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MATERIALS AND METHODS 
Yeast strains, plasmids and growth media—The yeast S. cerevisiae strains 
and plasmids used in this study are listed in Table 2-1 and Table 2-2. Single 
deletion mutants were obtained from the yeast knock-out deletion collection 
(Invitrogen). Double mutants were obtained by tetrad dissection. Parental ρ+ cells 
were used to generate ρ° derivatives by growing in yeast extract peptone 
dextrose   (YPD)   medium   containing   20   μg/ml   ethidium bromide to the early 
stationary phase. ρ° strains were confirmed by inability to grow on yeast extract 
peptone glycerol ethanol (YPGE) medium, the absence of mitochondrial DNA by 
DAPI staining, and the failure to complement ρ− tester strains for growth on 
YPGE medium.  
To construct a CLD1-overexpression plasmid, a 1338-bp sequence containing 
the entire open reading frame of CLD1 was amplified from yeast genomic DNA 
using an EcoRI-tagged   forward   primer   CLD1_EcoRI_F   (5’-
TATAGAACATGAATTCAAAAGTGAGCTGCAATGAGCA) and an XbaI-tagged 
reverse   primer   CLD1_XbaI_R   (5′- ATTTTGAGATTCTAGAAAGAAGAAAAA-
TAGCGGCGA -3′).   The   PCR   products   were   purified   using   the  Wizard   SV  Gel  
and PCR Clean-up System (Promega). The purified DNA fragments were ligated 
into pYPGK18 cut with EcoRI and XbaI, downstream of the PGK1 promoter. All 
the plasmids were amplified and extracted using standard protocols. The 
plasmids were transformed into yeast strains using a one-step transformation 
protocol. 





Table 2-1 Strains and plasmids used in this study  
BY4741 MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0 Invitrogen 
BY4742 MATα  his3Δ1  leu2Δ0  lys2Δ0  ura3Δ0 Invitrogen 
crd1Δ MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  crd1Δ::KanMX6 Invitrogen 
cld1Δ MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  cld1Δ::KanMX6 Invitrogen 
taz1Δ MATa his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  taz1Δ::KanMX6 this study 
cld1Δtaz1  Δ 
MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  cld1Δ::KanMX6  
taz1Δ::KanMX6 this study 
mig1Δ MATα  his3Δ1  leu2Δ0  lys2Δ0  ura3Δ0  mig1Δ::KanMX6   Invitrogen 
hap2Δ MATα  his3Δ1  leu2Δ0  lys2Δ0  ura3Δ0  hap2Δ::KanMX6 Invitrogen 
hap3Δ MATα  his3Δ1  leu2Δ0  lys2Δ0  ura3Δ0  hap3Δ::KanMX6 Invitrogen 
hap4Δ MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  hap4Δ::KanMX6 Invitrogen 
hap5Δ MATa  his3Δ1  leu2Δ0  met15Δ0  ura3Δ0  hap5Δ::KanMX6 Invitrogen 
BY4741 ρ° ρ° mutant derived from BY4741 this study 
crd1Δ  ρ° ρ° mutant derived from BY4741 crd1Δ this study 
cld1Δ  ρ° ρ° mutant derived from BY4741 cld1Δ this study 
taz1Δ  ρ° ρ° mutant derived from BY4741 taz1Δ this study 
cld1Δtaz1Δ  ρ° ρ° mutant derived from BY4741 cld1Δtaz1Δ this study 
pYPGK18 2μm,  LEU2 (Vaz et al., 2003) 
pYPGK18CLD1 
derived from pYPGK18, expression CLD1 from PGK1 
promoter this study 
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Synthetic complete (SC) medium contained adenine (20.25 mg/L), arginine (20 
mg/L), histidine (20 mg/L), leucine (60 mg/L), lysine (200 mg/L), methionine (20 
mg/L), threonine (300 mg/L), tryptophan (20 mg/L), uracil (20 mg/L), yeast 
nitrogen base without amino acids (Difco), all the essential components of 
DIFCO vitamin (inositol-free), 0.2% ammonium sulfate, and glucose (2%). 
Inositol   (75   μM)   was   supplemented   in   all   media   used   in   this   study.   Synthetic  
dropout media contained all ingredients mentioned above except for the amino 
acid used as a selectable marker, and were used to culture strains containing a 
plasmid.  
 
Chronological life span—Yeast chronological life span is determined by 
survival of non-dividing cells in a prolonged stationary culture (Fabrizio and 
Longo, 2003). A standard protocol previously described was followed (Hu et al., 
2013) to assess chronological life span. In brief, individual colonies were 
inoculated in 10 ml of SC glucose medium and incubated overnight. The cultures 
were then diluted in 50 ml of SC medium, and cells were allowed to grow until 
saturation. Viable cells were measured every 2 or 3 days by counting colonies 
that were serially diluted and plated on YPD plates and represented as 
percentage of cells at day 2. The viability is considered to be 100% at or before 
day 2.  
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Spotting assay—Cells were pre-cultured in SC medium to the early stationary 
growth   phase   at   30°C   and   washed   with   sterile   water.   Three   μL   aliquots   of   a  
series of 10-fold dilutions of 0.5 units of A550 cells were spotted onto indicated 
plates and incubated at 30°C.  
 
Real-Time quantitative PCR (RT-qPCR) analysis—Cells were grown to the 
indicated growth phase and harvested at 4°C. Total RNA was extracted using hot 
phenol (Kohrer and Domdey, 1991) and purified using the RNeasy Mini Plus kit 
(QIAGEN, Valencia, CA). Complementary DNA (cDNA) was synthesized using 
the First Strand cDNA Synthesis Kit (Roche Applied Science, Indianapolis, IN) 
according  to  the  manufacturer’s  manuals.  RT-qPCR reactions were performed in 
a   20   μL   volume   using  Brilliant   III   Ultra-Faster SYBR Green QPCR Master Mix 
(Agilent Technologies, Santa Clara, CA).  Triplicates were included for each 
reaction. The primers for RT-qPCR are listed in Table 2-2. RNA levels were 
normalized to ACT1. Relative values of mRNA transcripts are shown as fold 
change relative to indicated controls. Primer sets were validated according to 
Methods and Applications Guide from Agilent Technologies. Optimal primer 
concentrations were determined, and primer specificity of a single product 
monitored by a melt curve following the amplification reaction. All the primers 
were validated by measurement of PCR reaction efficiency and have calculated 
reaction efficiencies between 95-105%. 
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Table 2-2 Real-time PCR primers used in this study.  
 
    
Gene Primers Sequence (5' to 3')  
ACT1 Forward TCCGGTGATGGTGTTACTCA 
this study 
  Reverse GGCCAAATCGATTCTCAAAA 
PGS1 Forward TTTGCTCCAACTCACTCGTCCTCA 
this study 
  Reverse ATTGCCAAATGGAGAAGGGTTCGC 
GEP4 Forward AAAGGCCGTGGTCTTGGATAAGGA 
this study 
  Reverse ATTGGAACCGGCGGTATTGCTAA 
CRD1 Forward TGCGGCGATAATTCTGGGTAGAGA 
this study 
  Reverse ATTCCATGCCACACGACCAGGATA 
CLD1 Forward ACTGGCTTTGGCTTTATGGCGAT 
this study 
  Reverse TCCAGGTACAAGTGATGCCCTGA 
TAZ1 Forward CGAAGCCATCTTGGGTCCATGTT 
this study 
  Reverse CAATGGGCGGCTTTGTTGCTTCT 
ADH1 Forward GGTCTAGGTTCTTTGGCTGTT 
this study 
  Reverse CACCACCGATGGATCTGAATAA 
ADH2 Forward GTACTGTTGTCTTGGTTGGTTTG 
this study 
  Reverse GTAAGAGCCGACAATGGAGATAG 
PGK1 Forward AGGCTTCTGCCCCAGGTTC (Szijgyarto et 
al., 2011a)   Reverse CAGCACGTTGTGGCAAGTC 
GAPDH Forward AGTCTTTTGGGTGGCGGTCA (Szijgyarto et 
al., 2011a)   Reverse ACATTGACGCTGGTGCCAAG 
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Measurement of respiration—Cell respiration was analyzed in a closed 500 PL 
chamber equipped with a micro Clark-type oxygen electrode (Oxygraph plus 
system, Hansatech) at 30°C. Cells grown to the logarithmic phase were mixed in 
fresh growing media using a protein concentration of 2 mg/mL following 
measurements of basal respiration. State 4 and 3 respiration was determined in 
the presence of 4 PM  oligomycin  and  5  μM  FCCP,  respectively.  KCN (0.2 mM) 
was added at the end of the experiment to inhibit cytochrome c oxidase to 
normalize for (subtract) cytochrome c oxidase independent oxygen consumption. 
Oxygen consumption was recorded on a computer and analyzed with the 
Oxygraph plus software. Respiration rates are defined as consumed O2 
(nmol)/min∙total  protein  (mg). 
Determination of ATP concentrations—Yeast cells were cultured to the 
logarithmic phase and flash-frozen with liquid nitrogen. ATP levels were 
determined by the bioluminescence method described previously (Lee et al., 
2010).  
Determination of ethanol concentrations—Yeast cells were cultured in 10-mL 
growth medium for the indicated times to the logarithmic phase after inoculation 
at A550 of 0.05, and cells were pelleted by a 5-min centrifugation at 3,000 rpm. 
Supernatants were used to determine ethanol concentrations in the media. An 
ethanol colorimetric assay kit from BioVision was used to assay ethanol 




Mitochondrial aconitase activity—Cultures (2L) of yeast cells in the mid-
logarithmic phase were harvested for isolation of mitochondria. Mitochondria 
were isolated as described previously (Diekert et al., 2001). Briefly, spheroplasts 
generated by zymolyase treatment were ruptured by Dounce homogenization, 
and mitochondria were obtained by differential centrifugation. Total mitochondrial 
protein concentration was determined using the BCA protein assay (Pierce 
Protein). Mitochondrial aconitase activity was determined in mitochondrial 
extracts (50-μg   protein)   using   an   aconitase-isocitrate dehydrogenase-coupled 
assay, in which NADPH formation was monitored at A340 for 1 h (Gardner, 2002). 
Determination of CL by mass spectrometry —Total lipid extracts from 10 mg 
of cells (dry weight) were analyzed by HPLC-MS as described previously 






Deletion  of  CLD1  rescues  growth  and  life  span  defects  of  the  taz1Δ  mutant.   
Deacylation of CL in the absence of tafazzin leads to a decreased ratio of 
CL/MLCL and decreased unsaturated CL (Acehan et al., 2011; Gu et al., 2004; 
Valianpour et al., 2002; Xu et al., 2006), either of which may be responsible for 
cellular defects in tafazzin-deficient cells. We wished to distinguish between 
decreased CL/MLCL ratio vs. decreased unsaturated CL as the mechanism 
underlying the defects in the taz1Δ mutant. Blocking CL deacylation by deletion 
of CLD1 prevents the decrease in CL/MLCL ratio (Beranek et al., 2009). 
However, the CL that is synthesized de novo but not remodeled is mostly 
saturated, in contrast to remodeled CL in wild type (WT) cells, which is mostly 
unsaturated (Beranek et al., 2009). To determine if the decreased CL/MLCL ratio 
is responsible for taz1Δ defects, we determined the effects of CLD1 deletion in 
taz1Δ mutants. Interestingly, deletion of CLD1 rescued the respiratory growth 
defect of the taz1Δ mutant (Fig. 3-2A). Because mitochondrial respiration varies 
in strains with different genetic backgrounds (Ocampo et al., 2012) and the 
presence of polymorphic mitochondrial DNA can contribute to differences in 
mitochondrial respiration (Dimitrov et al., 2009), we assayed the effects of CLD1 
deletion   independent  of  mitochondrial   respiration.     To  do  so,  we  constructed  ρ0 
strains (which lack mitochondrial DNA) of the WT and CL mutants. While CL 
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deficient cells grow normally on glucose (Fig. 3-2A), which can be fermented, 
growth on glucose is compromised in the mutants if they lack mitochondrial DNA 
(Fig. 3-2B). Deletion of CLD1 rescued this growth defect (Fig. 3-2B). We 
predicted that CL deficient cells would exhibit a decreased chronological life span 
similar to the decreased replicative life span observed in these cells (Zhou et al., 
2009). As shown in Fig. 3-2C, both crd1Δ and taz1Δ mutants exhibited a 
dramatic decrease in chronological life span. Deletion of CLD1 partially rescued 
the decrease in taz1Δ life span, as the life span of taz1Δcld1Δ was almost similar 
to that of WT (Fig. 3-2C). The observation that deletion of CLD1 suppresses the 
defects in taz1Δ indicates that deacylation of CL is deleterious in the absence of 
tafazzin, and that the decreased CL/MLCL ratio but not decreased CL 
























Fig. 3-2: Deletion of CLD1 rescues growth and chronological life span 
defects in taz1Δ. (A) Serial 10-fold dilutions of WT, crd1Δ, cld1Δ, taz1Δ, and 
crd1Δtaz1Δ cells were spotted on synthetic complete medium with 2% glucose 
or 2% ethanol as carbon sources. Plates were incubated at 30°C for 3 days. (B) 
Serial 10-fold dilutions of respiration-incompetent  (ρ0) cells of the above mutants 
were spotted on synthetic complete medium with 2% glucose. (C) Chronological 
life span of WT, crd1Δ, cld1Δ, taz1Δ, and crd1Δtaz1Δ cells was determined as 
described  under  “Experimental  Procedures.”  The  data  depicted  in  the  figure  is  a  




CLD1 expression is highly regulated in response to growth phase, glucose 
availability and respiratory activity. 
The finding that cld1Δ rescued respiratory defects in taz1Δ suggested that CLD1 
expression plays a role in respiration.  We first compared expression of CL 
biosynthetic genes, including PGS1, GEP4, CRD1, CLD1, and TAZ1, in 
logarithmically growing cells (in which energy is generated primarily from 
glycolysis) and in cells in the stationary phase (during which energy is generated 
from respiration). Expression of all the CL biosynthetic genes was increased in 
the stationary phase (Fig. 3-3A). However, while PGS1, GEP4, CRD1, and TAZ1 
were increased about 3-5 fold, CLD1 was increased by about 10-fold in the early 
stationary phase and more than 30-fold in the later stationary phase (Fig. 3-3A). 
The large increase in CLD1 expression suggests that levels of unsaturated CL 
may be increased during stationary phase. This was in fact observed (Fig. 3-3B). 
Specifically, in the C68 cluster, the most unsaturated CL (C68:4, m/z 699.5) was 
abundant, while a more saturated species (C68:2, m/z 701.5) was less abundant 
in stationary phase cells. Conversely, the C68:4 CL was much less abundant 
than C68:2 in logarithmically growing cells. This is also evident in the C60 cluster 
as the most saturated CL (C60:0, m/z 647.4) was absent from stationary cells but 
clearly present in logarithmically growing cells. Deletion of CLD1 prevents CL 
remodeling and leads to decreased unsaturated CL (Beranek et al., 2009). As 
expected, cld1Δ exhibited a decreased degree of unsaturated CL compared to 






















Fig. 3-3: Increased CLD1 expression in the stationary phase is 
concomitant with increased CL unsaturation. (A) WT cells were grown in 
SC medium to the early-logarithmic (EL), mid-logarithmic (ML), early-
stationary (ES), and stationary (S) growth phases, and PGS1, GEP4, CRD1, 
CLD1, and TAZ1 expression was quantified by RT-PCR as described under 
“Experimental   Procedures.”   Values   of   each   gene   were   normalized to the 
internal control ACT1 and are represented as fold change relative to those in 
EL. Data shown are mean ± S.E. (n = 3). (B) Cells grown in YPD in the 
logarithmic and stationary phases were extracted for CL acyl composition 
analysis by HPLC-mass spectrometry,   described   under   “Experimental  
Procedures.”  (C)  WT  and  cld1Δ cells grown in SC media in the logarithmic and 
stationary phases were extracted for CL acyl composition analysis by HPLC-




were greater in stationary phase than in log phase cld1Δ cells. This finding 
suggests that an as yet unidentified mechanism regulates CL saturation in the 
absence of Cld1. 
 
Increased CLD1 expression in the stationary phase, during which glucose is 
exhausted and cells shift from fermentation to oxidative phosphorylation, 
suggested that CLD1 may be transcriptionally regulated in response to glucose 
availability and the need to respire. To test this prediction, we examined the 
expression of CLD1 in response to acute removal of glucose and in respiration-
deficient  cells   (ρ0 cells). As expected, expression of CLD1 but not the other CL 
biosynthetic genes was greatly increased in response to glucose starvation, by 6-
fold and 10-fold, during 30-min and 60-min starvation, respectively (Fig. 3-4A). 
Furthermore, CLD1 transcription  was  increased  in  the  stationary  phase  in  ρ+ cells 
but   not   in   respiration   incompetent   ρ0 cells (Fig. 3-4B). These findings indicate 
that CLD1 expression is upregulated during respiratory conditions and in 
response to glucose deprivation.  
Using the Promoter Database of Saccharomyces cerevisiae (SCPD) to search 
for putative regulatory elements in the upstream region of the CLD1 gene, we 
identified consensus sequences for Hap2 and Mig1 (Fig. 3-4C), transcription 
factors that mediate activation of respiratory gene expression and glucose 
repression, respectively (Nehlin and Ronne, 1990; Pfeifer et al., 1989; 
















































Fig. 3-4: CLD1 expression is increased in response to respiration and 
activated by HAP. (A) Glucose limitation. WT cells harvested in the mid-
logarithmic phase were washed with pre-warmed media with or without 
glucose and resuspended in fresh media with or without glucose for 30-min 
and 60-min. Analyses of PGS1, GEP4, CRD1, CLD1, and TAZ1 expression 
was determined using RT-qPCR and normalized to ACT1, as described 
under   “Experimental   Procedures.”   The   data   represent   as   fold   change  
relative to expression in media containing glucose and include the mean ± 
S.E. (n = 6). (B) Respiratory competency. ρ+ and  ρ0 cells were grown to 
the mid-logarithmic (ML) and early stationary (ES) phases. The values 
shown  represent  the  fold  change  relative  to  expression  of  WT  ρ+ cells in ML, 
and include mean ± S.E. (n = 6). (C) Sequence alignment depicting 
consensus sequences for Mig1 and Hap2 in the upstream region of the 
CLD1 gene using the Promoter Database of Saccharomyces cerevisiae 
(SCPD).  1 indicates a 100% match with putative consensus sequences, and 
0.88 and 0.82 indicates one mismatch. (D) Effect of the HAP complex. 
Expression was determined in hap2Δ, hap3Δ, hap4Δ, and hap5Δ cells 
grown to the mid-logarithmic phase. Data shown are mean ± S.E. (n = 6). (E) 
Effect of MIG1. Expression was determined in WT and mig1Δ cells grown to 
the mid-logarithmic phase. Data shown are mean ± S.E. (n = 3). 
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CLD1. As seen in Fig. 3-4D, CLD1 expression in the stationary phase was 
greatly reduced in hap2Δ,  hap3Δ,  hap4Δ,  and  hap5Δ mutants, indicating that the 
HAP complex up-regulates CLD1 transcription. Mig1 has been shown to repress 
gene expression in the presence of glucose (Santangelo, 2006; Schuller, 2003). 
If Mig1 repressed CLD1 transcription in the presence of glucose, CLD1 
transcription would be increased in mig1Δ cells. However, CLD1 transcription in 
mig1Δ  cells was decreased in these conditions (Fig. 3-4E). Thus, Mig1 appears 
to be a positive regulator of CLD1 expression. This is consistent with reported 
activator activity of Mig1 (Bu and Schmidt, 1998; Wu and Trumbly, 1998). Taken 
together, these findings indicate that expression of CLD1 is increased in 
response to respiration conditions, and this increase is mediated by the HAP and 
Mig1 transcriptional factors. 
 
Constitutive overexpression of CLD1 leads to decreases in respiration and 
mitochondrial aconitase activity, and instability of mitochondrial DNA. 
 
As expression of CLD1 is deleterious to tafazzin-deficient cells, we predicted that 
increased CLD1 expression alters metabolism and perturbs cell growth. 
Consistent with this, cell growth was decreased when CLD1 was overexpressed 
(Fig. 3-5A). One possible explanation for this is that increased CLD1 expression 
perturbs respiration. In support of this, basal respiration in mitochondria from 
cells that overexpressed CLD1 was about half that of control cells (Fig. 3-5B). 
5 
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This difference was even more pronounced comparing the maximum respiratory 
capacity that was achieved by uncoupling the respiratory chain with 
trifluorocarbonylcyanide phenylhydrazone (FCCP). Therefore, constitutive 
overexpression of CLD1 decreases mitochondrial respiration.  
A possible mechanism to account for decreased respiration in CLD1 
overexpressing cells is suggested by the observation that over 60% of cells 
became cytoplasmic petites. The respiratory growth deficiency of the petites was 
not  complemented  by  crossing   to  ρ- tester strains, and mitochondrial DNA was 
not observed in the petite cells stained with DAPI. As aconitase is required for 
mitochondrial genome maintenance (Chen et al., 2005), we tested the possibility 
that aconitase activity might be decreased in cells overexpressing CLD1. In fact, 
the kinetics of aconitase enzymatic activity in mitochondria from CLD1 
overexpressing cells exhibited a 60% decrease compared to cells 
overexpressing empty vector (Fig. 3-5C). Taken together, these studies indicate 
that increasing CL deacylation by constitutive overexpression of CLD1 impairs 
cell growth and respiration and decreases mitochondrial DNA stability, 
suggesting that deacylation of CL is an important control point for mitochondrial 
function. 
Increased fermentation compensates for decreased respiration in cells 
overexpressing CLD1. 
As respiration was decreased in cells overexpressing CLD1, we expected to see 






Fig. 3-5: Overexpression of CLD1 decreases cell growth, respiration, 
and mitochondrial aconitase activity. (A) Growth of WT cells in SC 
media overexpressing CLD1 or empty vector (EV). Cells were inoculated at 
an initial A550 of 0.05, and A550 was measured at the indicated times. The 
growth curves shown in the figure are representative of three experiments. 
(B) Oxygen consumption was measured in logarithmically growing cells 
using a Clark-type   electrode   as   described   under   “Experimental  
Procedures.”   Data   shown   are  mean   ±   S.E.   (n = 3-6). (C) The kinetics of 
aconitase enzymatic activity in mitochondria from control and CLD1 
overexpressing cells grown to the logarithmic phase were determined as 
described  under  “Experimental  Procedures”.  Data  shown  are  mean  ±  S.E.  
(n = 3). 
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cellular ATP production can be estimated by the decrease in oxygen 
consumption resulting from the addition of oligomycin, an inhibitor of ATP 
synthesis. Under basal conditions, the decrease in respiration caused by 
oligomycin was significantly less in mitochondria from CLD1 overexpressing cells 
than in controls (Fig. 3-5B), suggesting that mitochondrial ATP synthesis was 
decreased. Interestingly, however, total ATP levels were actually higher in CLD1 
overexpressing cells (Fig. 3-6A). This suggested that cells may compensate for 
the respiratory loss by increasing ATP generation from fermentation. Consistent 
with this, ethanol production was significantly higher in CLD1-overexpressing 
cells than in controls (Fig. 3-6B).  To determine if up-regulation of genes in 
glycolysis/fermentation could account for increased ethanol production, we 
analyzed expression of GAPDH and PGK1, which encode enzymes that catalyze 
key steps in glycolysis (glyceraldehyde-3-P dehydrogenase and 
phosphoglycerate kinase, respectively), as well as ADH1 and ADH2, which 
encode the fermentation enzyme alcohol dehydrogenase. As seen in Fig. 3-6C, 
expression of ADH1 and ADH2 was increased 2-fold, which most likely accounts 
for the increase in ethanol production. Expression of GAPDH and PGK1 was not 
altered. These findings indicate that overexpression of CLD1 leads to decreased 






A deficiency in CL reacylation catalyzed by tafazzin is deleterious in eukaryotes 
(Acehan et al., 2011; Gu et al., 2004; Schlame et al., 2003; Valianpour et al., 
2002; Vreken et al., 2000; Xu et al., 2006), most notably in humans where it 
leads to the life-threatening disorder BTHS (Barth et al., 1983; Barth et al., 2004; 
Barth et al., 1999). The loss of tafazzin results in perturbation of CL metabolism. 
Specifically, the CL/MLCL ratio is decreased, as are the levels of unsaturated CL 
species. Although many studies suggest that the deleterious effects of tafazzin 
deficiency result from the absence of unsaturated CL (Schlame et al., 2003; 
Schlame and Ren, 2006; Schlame et al., 2002; Valianpour et al., 2003; Xu et al., 
2003), no reports to date have distinguished between decreased unsaturated CL 
and decreased CL/MLCL as the cause of the cellular defects. In the current study, 
we addressed this question by characterizing the effects of CLD1 deletion on 
tafazzin deficient yeast cells. The cld1Δ mutant has decreased unsaturated CL 
(similar to the taz1Δ mutant), but the CL/MLCL ratio is not decreased. We report 
that cld1Δ rescues growth and respiration defects of the taz1Δ mutant, indicating 
that the decreased CL/MLCL ratio, and not decreased unsaturated CL, leads to 































Fig. 3-6: Overexpression of CLD1 leads to increased ATP and ethanol. 
(A) ATP levels in logarithmically growing cells overexpressing CLD1 or 
empty   vector   (EV)   were   determined   as   described   under   “Experimental  
Procedures.”   Data   shown   are   mean   ±   S.E.   (n = 3). (B) Ethanol 
concentrations   were   determined   as   described   under   “Experimental  
Procedures”.  Data  shown  are  mean  ±  S.E.  (n = 6) (*p<0.05, **p<0.01). (C) 
WT cells overexpressing CLD1 or EV grown to the logarithmic phase were 
harvested for mRNA extraction. Expression of ADH1, ADH2, GAPDH, and 
PGK1 was determined using RT-qPCR  as  described  under   “Experimental  
Procedures”.  Values  of  each  gene  were  normalized   to   the   internal   control  
ACT1. Transcripts normalized to ACT1 are represented as fold change 





Interestingly, the double mutant cld1Δtaz1Δ exhibited defective growth in 
glycerol/ethanol  medium   at   37˚C   as   reported   in   Beranek   et   al   (Beranek et al., 
2009). We tested growth of WT, crd1Δ, cld1Δ, taz1Δ, and cld1Δtaz1Δ cells in 
media containing glucose, glycerol, ethanol, or glycerol/ethanol as carbon 
sources. Indeed, we found that the double mutant grew poorly compared to WT 
when glycerol/ethanol was used as carbon source, similar to the observation of 
Beranek et al.  However, in these carbon sources, we did not observe respiratory 
growth defects in taz1Δ at  30˚C.  Although   taz1Δ exhibited decreased growth in 
glycerol/ethanol at  37˚C,  high  temperature  stress  complicates  respiration  defects.  
In marked contrast, we observed that taz1Δ cells exhibit a significant respiratory 
growth  defect  in  ethanol  medium  at  30˚C.    Under  these  conditions,  we  observed  
that the double mutant rescued the respiratory defects of taz1Δ. As cld1Δ 
restores CL levels but not unsaturated CL species in taz1Δ, this finding indicates 
that rescue of respiratory growth of taz1Δ by cld1Δ results from restoration of CL 
levels.  
 
While deletion of CLD1 does not appear to affect growth, expression of the gene 
is deleterious in the absence of reacylation, as taz1Δ cells that have the wild type 
CLD1 gene are defective, while those carrying the cld1Δ mutation grow normally. 
To gain insight into the mechanism underlying the deleterious effects of 
increased CLD1, we characterized growth and mitochondrial function of cells 
6 
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overexpressing this gene. Interestingly, overexpression of CLD1 resulted in 
increased ATP levels (Fig. 3-6A) despite a significant reduction in mitochondrial 
respiration (Fig. 3-5B).  Two possibilities may explain this seemingly surprising 
finding.  First, overexpression of CLD1 leads to growth slowdown, therefore less 
ATP is required and utilized to maintain cellular functions.  Second, CLD1 
overexpression shifts metabolism from respiration toward glycolysis and 
fermentation (Fig. 3-7), compensating for defective oxidative phosphorylation.  
This indicates that regulation of Cld1-mediated deacylation of CL influences 
energy metabolism by modulating the relative contribution of glycolysis and 
respiration.  CL is an essential component of oxidative phosphorylation 
complexes.  For example, it was identified in the crystal structure of cytochrome c 
oxidase (Shinzawa-Itoh et al., 2007), the proposed rate-limiting enzyme of the 
electron transport chain (reviewed in (Huttemann et al., 2012)) and is required for 
optimal enzyme function and activity (Koshkin and Greenberg, 2000).  Therefore, 
reduced mitochondrial respiration in CLD1 overexpressing cells would be 
expected if the CL pool is modified. (We hypothesize that during stationary 
growth, when oxidative phosphorylation is used, CL may be tuned towards 
increased membrane fluidity or association with the supercomplexes).  
Furthermore, such alterations lead to mitochondrial DNA instability. 
Apparently, there is yet another level of regulation of the CL metabolic pathway 
intersecting with cytochrome c oxidase regulation.  We show here that CLD1 
gene regulation is mediated by the Hap2/3/4/5p transcription factor complex (Fig. 
3-4E), which is also a crucial regulator of cytochrome c oxidase subunit V 
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isoforms Va and Vb (Kwast et al., 1999).  These isoforms result in an enzyme 
with higher affinity for oxygen when the substrate is scarce.  Furthermore, 
overexpression of components of the Hap2/3/4/5p complex rescues cytochrome 
c oxidase deficiencies (Fontanesi et al., 2008).  In another example of coordinate 
control, regulation of COX4 translation requires Pgs1, the enzyme that catalyzes 
the committed step of CL synthesis (Su and Dowhan, 2006). Taken together 
these findings suggest an integrated and concerted response to environmental 
stress that affects the CL pathway and oxidative phosphorylation, both of which 
are interconnected.   
Our findings suggest that increased CLD1 is deleterious to cells because it 
decreases respiration. However, CLD1 expression was increased during 
respiratory growth and regulated by the HAP complex (Fig. 3-4), the 
transcriptional activator that responds to respiratory growth signals. This raises 
the question of what is the function of the CL remodeling pathway, and the 
corollary question of why is CLD1 expression increased in response to 
respiratory conditions.  We speculate that the function of CL remodeling is to 
remediate the deleterious effects of respiration (Fig. 3-7). In support of this 
possibility, superoxides generated by respiratory complex III cause peroxidation 
of CL and decreased cytochrome c oxidase activity (Paradies et al., 2000; 
Paradies et al., 2001; Paradies et al., 1998). Exogenous supplementation of CL, 
but not peroxidized CL or other phospholipids, rescued both reduced activity of 
cytochrome c oxidase and increased generation of ROS in reperfused heart 
(Paradies et al., 2001; Petrosillo et al., 2007). In this light, CL remodeling may be  
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Fig. 3-7: Proposed model.  Regulation of Cld1-mediated deacylation of CL 
influences energy metabolism.  CLD1 expression is upregulated in 
response to increased respiration.  Increased CLD1 expression modulates 
the relative contributions of oxidative phosphorylation and glycolysis to 
cellular energy production. We speculate that the function of CL 
deacylation, which is increased during respiratory conditions that are known 
to increase oxidative stress, is to remove peroxidized acyl chains from 




a mechanism whereby damaged fatty acyl chains are replaced. Although 
different approaches have been used, this proposed model is similar to the 
model described in Baile et al (Baile et al., 2013), in which they suggested a 
feedback loop between oxidative phosphorylation and CL remodeling. 
Specifically, they found that CLD1 expression is regulated by carbon sources, 
and the activity of Cld1 is increased by dissipating the mitochondrial membrane 
potential (Baile et al., 2013). They suggested that CL remodeling functions to 
increase oxidative phosphorylation efficiency and/or replace oxidized CL.  
Our findings have implications for understanding the mechanism underlying 
BTHS. Many studies of BTHS have concluded that the disorder is due to the 
complete   lack  of   the   ‘normal’  unsaturated      (tetralinoleoyl,  or  L4)  CL   in   the  heart  
(Schlame et al., 2003; Schlame and Ren, 2006; Schlame et al., 2002; Valianpour 
et al., 2003; Xu et al., 2003). However, the current study indicates that in yeast, a 
total   lack  of   the  ‘normal’  unsaturated  CL  species   is  not  deleterious  to cells. The 
large number of mammalian phospholipases complicates the ability to distinguish 
between decreased CL/MLCL vs. decreased unsaturated CL in human cells. 
Gross and co-workers (Kiebish et al., 2013) reported that ablation of 
phospholipase iPLA2g in the mouse reduced MLCL levels by only ~50% 
indicating that other phospholipases deacylate CL. Mass spectrometry analysis 
of phospholipase activity identified at least four phospholipases that deacylate CL 
in vitro (Hsu et al., 2013). The identification of mammalian CL-specific 
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Inositol, a six-carbon cyclitol, is an essential metabolite. It serves as the 
precursor of inositol lipids and inositol phosphates (Carman and Han, 2011; 
Henry et al., 2012a; Michell, 2008; Michell, 2011), which play crucial roles in 
gene expression, signal transduction, lipid signaling, vesicle trafficking, and 
membrane biogenesis (De Camilli et al., 1996; Lemmon, 2003; Majerus and York, 
2009; Shen et al., 2003; Steger et al., 2003; van Meer et al., 2008a). Many types 
of cultured mammalian cells require supplementation of exogenous inositol for 
growth, and inositol-requiring mammalian cells and mutants of yeast undergo cell 
death in response to inositol deprivation (Culbertson and Henry, 1975; Eagle, 
1955; Eagle et al., 1957; Kao and Puck, 1968; Keith et al., 1977).  
Eukaryotic organisms can potentially obtain inositol from the environment, by the 
de novo synthesis of inositol from glucose, or via recycling of inositol by 
dephosphorylation of inositol phosphates. These processes are orchestrated to 
maintain intracellular inositol homeostasis. Inositol uptake in yeast (Lai et al., 
1995; Lai and McGraw, 1994) and mammals (Wolfson et al., 2000; Wolfson et al., 
1998), and inositol biosynthesis in yeast (Henry et al., 2014; Hirsch and Henry, 
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1986; Loewen et al., 2004) are affected by exogenous inositol. In mammals, 
inositol uptake is also regulated in response to glucose, pH, osmolality, growth 
factors, and other stimuli (Di Daniel et al., 2009; Fu et al., 2012; Miyakawa et al., 
1999; Novak et al., 1999; Olgemoller et al., 1993; Spizz and Pike, 1992; Uldry et 
al., 2004; Yorek et al., 1998). Inositol de novo synthesis is a highly conserved 
pathway that is carried out in two steps, of which the conversion of glucose-6-
phosphate to inositol-3-phosphate, catalyzed by the INO1 gene product inositol-
3-phosphate synthase, is rate-limiting (Eisenberg, 1967; Kindl and Hoffmann-
Ostenhof, 1964; Loewus and Kelly, 1962a; Loewus and Kelly, 1962b; Strausberg 
et al., 2002). The regulation of inositol biosynthesis has been intensively studied 
in yeasts (Bachhawat et al., 1995b; Carman and Han, 2011; Chen et al., 2007; 
Henry et al., 2012a; Loewen et al., 2004; Ye et al., 2013). In addition to the 
transcriptional regulation of INO1 in response to exogenous inositol (Henry et al., 
2014; Hirsch and Henry, 1986; Loewen et al., 2004), optimal inositol biosynthesis 
requires glycogen synthase kinase-3 (GSK-3) (Azab et al., 2007) and inositol 
pyrophosphates (Ye et al., 2013). Furthermore, Ino1 is posttranslationally 
regulated by phosphorylation (Deranieh et al., 2013), and enzyme activity is 
inhibited by the glycolysis intermediate dihydroxyacetone phosphate (DHAP) 
(Migaud and Frost, 1996; Shi et al., 2005). Mammalian INO1 expression is 
altered by estrogen, glucose, and lovastatin, and is regulated by the transcription 
factor E2F1 (Guan et al., 2003; Rivera-Gonzalez et al., 1998; Seelan et al., 2004; 
Seelan et al., 2011). Highly regulated inositol synthesis underscores the 
importance of maintaining inositol homeostasis.  
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The brain maintains a high level of free inositol (5–50 mM), which is about 100 
times higher than that in blood and other tissues (Palmano et al., 1977; Sherman 
et al., 1977; Stokes et al., 1983; Wong et al., 1987). Altered inositol levels in the 
brain are associated with psychiatric and neurological problems (Seelan et al., 
2009; Shi et al., 2006). For example, levels of inositol are altered in the brains of 
patients with Down’s syndrome (Acevedo et al., 1997; Berry et al., 1995), stroke 
(Rumpel et al., 2003), bipolar disorder (Belmaker et al., 2002; Shimon et al., 
1997), and suicide victims (Shimon et al., 1997). Although dietary inositol can 
cross the blood-brain barrier and enter the cerebrospinal fluid and brain 
parenchyma, this process is very slow (Aukema, 1994). Inositol levels in the 
brain primarily depend on inositol recycling and de novo synthesis (Williams et al., 
2002). However, the requirement of brain cells for inositol synthesis and the 
cellular consequences of perturbation of inositol synthesis in neuronal cells are 
not well studied. 
Lithium, a mood-stabilizer used for the treatment of bipolar disorder, is an 
uncompetitive inhibitor of inositol monophosphatase and inositol 
polyphosphatase (Allison and Stewart, 1971; Berridge et al., 1989; Pollack et al., 
1994), and causes a decrease in intracellular inositol by blocking inositol 
recycling and synthesis. The mood-stabilizer valproic acid (VPA) inhibits inositol 
biosynthesis by indirectly decreasing activity of the rate-limiting enzyme Ino1 (Ju 
and Greenberg, 2003; Shaltiel et al., 2004b; Vaden et al., 2001). Both drugs 
decrease cellular inositol and inositol 1,4,5-trisphosphate levels (Eickholt et al., 
2005; Shimshoni et al., 2007; Williams et al., 2002), indicating that inositol 
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depletion may attenuate inositol-dependent signaling. While inositol depletion 
may be therapeutically relevant (Berridge et al., 1989), another proposed target 
of mood-stabilizers is GSK-3 (Klein and Melton, 1996; Lucas and Salinas, 1997). 
The two major isoforms of GSK-3, GSK-3α and GSK-3β, share 85% sequence 
homology and are encoded by independent genes (Cohen and Frame, 2001). 
Both isoforms are expressed in the brain and have many regulatory functions in 
neural systems, including neurogenesis, neuronal structure, synaptic plasticity, 
and neuronal survival (Hur and Zhou, 2010). Lithium is a competitive inhibitor of 
GSK-3, and lithium treatment increases the inhibitory phosphorylation of this 
kinase (Klein and Melton, 1996; Lucas and Salinas, 1997; Ryves and Harwood, 
2001; Zhang et al., 2003). Lithium-induced GSK-3 phosphorylation is caused by 
disrupting the signaling complex of Akt, β-arrestin 2, and protein phosphatase 2A 
(Beaulieu et al., 2008). Previous studies have not linked lithium-mediated 
inhibition of GSK-3 to inositol depletion. Interestingly, however, the inositol-
depleting drug VPA has also been shown to inhibit GSK-3 activity (Chen et al., 
1999; Chen et al., 2006; De Sarno et al., 2002; Kim et al., 2005). Common 
cellular effects of inositol depletion and GSK-3 inhibition in response to lithium 
and VPA treatment suggest that inositol metabolism and GSK-3 activity may be 
interdependent. It has not been determined if inositol metabolism affects GSK-3 
activity in neuronal cells. Elucidating the interplay between inositol synthesis and 
GSK-3 in neuronal cells will have important implications for the pathophysiologic 
basis of a wide range of disorders in which inositol levels play a role. 
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In the current study, we characterized the role of inositol synthesis in proliferation 
of SK-N-SH neuroblastoma cells. We found that INO1 expression is essential for 
cell proliferation and neurite outgrowth. We further showed that inositol synthesis 
regulates GSK-3α activation, as inhibition of inositol synthesis by knocking down 
INO1 expression or exposure to VPA led to increased phosphorylation at Ser21 
of GSK-3α, which inactivates the kinase. This is the first demonstration in 
neuronal cells of the importance of inositol de novo synthesis, and the first report 
showing that inositol synthesis affects GSK-3α activation. These findings have 
implications for the therapeutic mechanisms of mood-stabilizers and suggest that 




MATERIALS AND METHODS 
 
Materials 
Dulbecco's Modified Eagle Medium (DMEM), Medium 199, and penicillin-
streptomycin solution (100X) were purchased from Invitrogen. Fetal bovine 
serum (FBS) and dialyzed FBS were purchased from Hyclone. Inositol, lithium 
chloride, valproic acid, glucose-6-phosphate, NAD+, inositol dehydrogenase, and 
diaphorase were purchased from Sigma. Control shRNA lentiviral particles and 
INO1 (also named ISYNA1) shRNA lentiviral particles, puromycin dihydrochloride, 
and polybrene were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
The protease inhibitors and phosphatase inhibitors were purchased from Roche. 
 
The rabbit polyclonal IgG against the Ino1 protein (H-300), mouse monoclonal 
IgG against actin (C-2), and anti-mouse IgG were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). The rabbit monoclonal IgG against phospho-
GSK-3α (ser21) (36E9), rabbit monoclonal IgG against GSK-3α (D80E6), rabbit 
monoclonal IgG against phospho-GSK-3β (Ser9) (D85E12), rabbit monoclonal 
IgG against GSK-3β (27C10), and anti-rabbit IgG were purchased from Cell 
Signaling Technology.  All the primary antibodies were diluted 1:1000 and 
secondary antibodies 1:5000 in dilution buffer containing 1X tris-buffered saline 
(TBS), 0.1% Tween-20 with 5% nonfat dry milk. 
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Cell culture  
SK-N-SH neuroblastoma cells were obtained from ATCC. Cells were regularly 
cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. 
For experiments to test effects of inositol deficiency, Medium 199 supplemented 
with 10% dialyzed FBS were used as inositol-deficient media. Inositol was added 
to this medium where indicated for inositol-rich media. All cells were cultured at 
37˚C in 95% air and 5% CO2. Of note, DMEM contains 40 μM inositol, and 
Medium 199 has 0.28 μM inositol. The dialyzed FBS contains trace amounts of 
small molecules.  
Establishment of stable cell lines 
SK-N-SH cells were transduced with lentiviral particles that contain 3 specific 
constructs targeting human INO1, or with control lentiviral particles containing 
non-specific scrambled shRNA. Stable cells were isolated in media 24 hours 
after the transduction with 5 μg/ml  puromycin  for  2  weeks.   
Proliferation assay 
Cell proliferation was carried out using a proliferation assay kit (CellTiter 96 
AQueous One Solution cell proliferation assay, Promega) and following the 
manufacturer’s instruction. Cells were inoculated at a concentration of 5,000 cells 
per well in 96-well plates. On the indicated days, the assay reagent containing 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
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2-(4-sulfophenyl)-2H-tetrazolium (MTS) was added and incubated at 37˚C for 4 
hours. Relative cell numbers were quantified by absorbance at 490 nm. The 
quantity of MTS formazan produced from MTS tetrazolium is directly proportional 
to the number of living cells (Cory et al., 1991).  
RNA isolation and real-time quantitative PCR (RT-qPCR) 
SK-N-SH cells were cultured in 6-well plates. Total RNA was extracted using the 
RNeasy Mini Plus kit (QIAGEN, Valencia, CA). Complementary DNA (cDNA) was 
synthesized using the First Strand cDNA synthesis Kit (Roche Applied Science, 
Indianapolis, IN) according to the manufacturer’s  manuals.  RT-qPCR reactions 
were   performed   in   a   20   μL   volume   using  Brilliant   III   Ultra-Faster SYBR Green 
QPCR Master Mix (Agilent Technologies, Santa Clara, CA).  Triplicates were 
included for each reaction. The primers for RT-qPCR are listed in Table 3-1. RNA 
levels were normalized to succinate dehydrogenase, SDHA. Relative values of 
mRNA transcripts are shown as fold change relative to indicated controls.  
SDS-PAGE and Western blots 
Cell extracts were obtained by breaking cells in lysis buffer containing 50 mM 
Tris, 125 mM sodium chloride, 1% NP-40, 2 mM EDTA, 1x protease inhibitor 
cocktail, and 1x phosphatase inhibitor cocktail and were clarified twice by 10 min-
centrifugation at 13,000 g at 4°C to remove cell debris.  Protein concentration 
was determined using the BCATM protein assay (Pierce Protein), with bovine 
serum albumin as the standard. Cell extracts containing 20 μg   protein were 













Table 3-1 Real-time PCR primers used in this study.  
   
Gene Primers Sequence (5' to 3') 
SDHA Forward CGAACGTCTTCAGGTGCTTT 
  Reverse AAGAACATCGGAACTGCGAC       
INO1 Forward CTGCATCGAGAACATCCTCAG                         
  Reverse GTTCAACATAGGGTAGGTGGC                         
SMIT1 Forward AAGGTGGTGGTTCGAATCTG     
  Reverse CCACAGGATTGTTTTGGGTC     
HMIT Forward CATCTGCAGAATGGTTGCAC     
  Reverse AACTCGCCGAGCTTTAATTG       
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electrotransferred to a polyvinylidene difluoride (PVDF) membrane (Millipore). 
The membrane was incubated with antibodies and visualized using ECL 
substrate (Pierce Protein). ImageJ software was used to quantify the intensities 
of bands. 
 
Measurement of intracellular inositol  
Intracellular inositol was measured as described previously (Ju and Greenberg, 
2003; Ye et al., 2013) with minor modifications. Briefly, cell extracts were 
obtained in lysis buffer containing 50 mM Tris, 125 mM sodium chloride, 1% NP-
40, 2 mM EDTA and were clarified twice by 10 min-centrifugation at 13,000 g at 
4°C to remove cell debris. Cell extracts containing 50 μg  protein were used to 
measure intracellular inositol. Protein was precipitated using ice-cold 7.5% 
perchloric acid. After centrifugation, perchloric acid in the supernatants was 
removed by titration to pH 7.0 with ice-cold 10 M potassium hydroxide. The cell 
extracts were again clarified by centrifugation for 5 min at 2,000 g at 4°C. The 
supernatants were collected, and intracellular inositol was measured by enzyme-
coupled fluorescence assay (Maslanski and Busa, 1990). Inositol content in cell 





Measurement of the de novo synthesis of inositol  
The de novo synthesis of inositol was measured in crude cell extracts as 
described previously (Azab et al., 2007; Barnett et al., 1970; Chen and 
Charalampous, 1966; Shi et al., 2005) with modifications. Crude cell extracts 
containing 50 μg protein obtained in lysis buffer containing 50 mM Tris, 125 mM 
sodium chloride, 1% NP-40 were used to test the activity of inositol de novo 
synthesis. The cell extracts were resolved using Amicon 10 KDa-cutoff 
centrifugal filters and washed with buffer containing 100 mM Tris acetate, pH 7.0, 
20 mM NH4Cl, and 2 mM dithiothreitol.  Endogenous inositol, glucose-6-
phosphate, and other small molecules were removed during this process. The 
protein extracts were resuspended in reaction buffer containing 100 mM Tris 
acetate, pH 7.7, 20 mM NH4Cl, 2 mM dithiothreitol, 0.8 mM NAD+, and 1 mM 
glucose-6-phosphate, and incubated at 37˚C for 1 hour. The reaction was 
stopped by adding 7.5% perchloric acid. After centrifugation, perchloric acid in 
the supernatants was removed by titration to pH 7.0 with ice-cold potassium 
hydroxide. After 5-min centrifugation at 2,000 g, the supernatants were resolved 
using ion exchange colomns filled with AG 1-X8 (200-400 mesh, formate form). 
The eluate containing inositol was collected and dried in an oven  at  70˚C.  The  
dried samples were resuspended in inositol assay buffer, and inositol produced 
from glucose-6-phosphate in this mixture was measured as described above (Ju 






Exogenous inositol is not essential for cell proliferation or maintaining inositol 
homeostasis in SK-N-SH cells. 
Inositol is an essential growth factor that is required for survival and proliferation 
of many types of cultured cells (Eagle et al., 1957). Inositol deficiency in these 
cells causes an arrest of cell growth, cytopathogenic defects, and cell death. 
However, some cells are able to proliferate in inositol-free or inositol-deficient 
culture media due to active inositol biosynthesis (Eagle et al., 1957). To 
determine if inositol is essential for SK-N-SH neuronal cells, we assayed cell 
growth in inositol-deficient media (Medium 199 with 10% dialyzed serum). 
Medium 199 contains only 0.28 μM inositol, which is significantly less than the 
minimal requirement (1 μM) reported for most types of cells (Eagle et al., 1957). 
As seen in Fig. 4-1A, proliferation of cells cultured in the inositol-deficient media 
was similar to that of cells grown in media supplemented with exogenous inositol. 
The ability of SK-N-SH cells to grow in inositol-deficient media indicates that the 
de novo synthesis of inositol provides sufficient inositol for cell proliferation. 
Interestingly, cells cultured in inositol-deficient media exhibited levels of 
intracellular inositol similar to those of cells grown in media supplemented with 
0.5-10 mM inositol (Fig. 4-1B). The homeostatic inositol pool in SK-N-SH cells 










Fig. 4-1: Exogenous inositol is not essential for cell proliferation or 
maintaining inositol homeostasis in SK-N-SH cells. (A) SK-N-SH cells 
were inoculated at a concentration of 5,000 cells per well in 96-well plates 
at day 0, and cell numbers were estimated by the proliferation assay 
described under “Materials and methods.” (B) Intracellular inositol levels 
were assayed in cells cultured in inositol-deficient media without (control) 
or with inositol supplement (0.5, 1, 5, 10 mM). The data shown in A and B 




Inositol biosynthesis is essential for cell proliferation. 
To understand if inositol biosynthesis is required for SK-N-SH cells, we 
decreased inositol biosynthesis by stably knocking down expression of the gene 
encoding inositol-3-phosphate synthase, INO1, which encodes the rate-limiting 
enzyme of inositol biosynthesis. Two knockdown lines of SK-N-SH cells were 
obtained, shRNA-INO1-1 and shRNA-INO1-2, which exhibited 60% and 82% 
decreases in INO1 expression, respectively (Fig. 4-2A). As expected, cell 
proliferation was dependent on the level of INO1 expression (Fig. 4-2B). 
Interestingly, neurite outgrowth was remarkably inhibited in cells in which INO1 
expression was decreased (Fig. 4-2C). These findings indicate that de novo 
inositol synthesis is essential for cell proliferation and neurite outgrowth in SK-N-
SH cells. 
 
Exogenous inositol does not regulate transcription of INO1, SMIT1, and HMIT, 
the genes for inositol biosynthesis or uptake. 
In yeast cells, exogenous inositol modulates the biosynthesis and uptake of 
inositol by controlling transcription of the inositol biosynthetic gene INO1 (Henry 
et al., 2014; Hirsch and Henry, 1986; Loewen et al., 2004) and the genes 
encoding inositol transporters (Lai et al., 1995; Lai and McGraw, 1994). To 
ascertain if this is a conserved mechanism regulating inositol metabolism in SK-

























Fig. 4-2: Inositol biosynthesis is essential for cell proliferation. (A) 
Western blot analysis of Ino1 and inhibitory phosphorylation levels of GSK-3α 
(Ser21) and GSK-3β (Ser9).  Actin was used as the loading control. 
Scrambled control and Ino1 knockdown (shRNA_INO1_1 and 
shRNA_INO1_2) SK-N-SH cells were cultured to about 70% confluence, and 
cells were refreshed with media containing 10% serum (+serum) or no serum 
(-serum) for 4 hours. Cells were harvested and lysed for Western blot analysis 
as described under “Materials and methods.” (B) Cell proliferation was 
assayed as described in Fig. 4-1A, and cell numbers were estimated 4 days 
after inoculation. The data shown are the average of four experiments + S.D. 
(C) Control and INO1 knockdown cells (about 1X106) were plated in 100-mm 
dishes and photographed at day 2 using a microscope at 200 X magnification. 
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INO1, Na+/inositol transporter SMIT1, and H+/inositol transporter HMIT in these 
cells. Cells were initially cultured in inositol-deficient media to deplete inositol. 
After supplementation with inositol (0.1, 1, 10 mM) for the indicated times, cells 
were harvested for mRNA analysis. As shown in Fig. 4-3A, mRNA levels of 
human INO1 were not affected by the addition of inositol. Consistent with this 
finding, INO1 protein levels were also not altered by exogenous inositol (Fig. 4-
3B). In addition, the genes encoding inositol transporters were not regulated by 
inositol, as mRNA levels of SMIT1 (Fig. 4-3C) and HMIT (Fig. 4-3D) were not 
significantly changed in response to exogenous inositol. Therefore, in contrast to 
regulation of inositol biosynthesis in yeast cells, the biosynthesis and uptake of 
inositol were not transcriptionally regulated in response to exogenous inositol in 
SK-N-SH cells. 
 
Decreased Ino1 protein levels leads to inactivation of GSK3α. 
Previous studies showed that lithium and VPA inhibit inositol synthesis (Allison 
and Stewart, 1971; Berridge et al., 1989; Ju and Greenberg, 2003; Pollack et al., 
1994; Shaltiel et al., 2004b; Vaden et al., 2001) and GSK-3 activity (Chen et al., 
1999; Chen et al., 2006; De Sarno et al., 2002; Kim et al., 2005; Klein and Melton, 
1996; Lucas and Salinas, 1997). To address the possibility that inositol synthesis 
affects GSK-3 activity, we measured levels of phosphorylation at Ser21 of GSK-












  Fig. 4-3: Exogenous inositol does not regulate transcription of the 
genes for inositol biosynthesis or uptake. (A) mRNA levels of INO1 
were measured in SK-N-SH cells incubated in the presence of inositol (0, 
0.1, 1, 10 mM) for the indicated times (1, 5, and 10 hours) after growth in 
inositol-deficient media. Values were normalized to the internal control 
SDHA (succinate dehydrogenase complex, subunit A). INO1 mRNA levels 
normalized to SDHA were represented as fold change relative to cells 
exposed to 0 mM inositol for 1 hour. (B) Western blot analysis of Ino1 
protein levels. SK-N-SH cells were cultured to reach about 70% confluence 
and then were incubated with either serum or inositol for indicated times. 
Cells were harvested and lysed for Western blot analysis as described 
under “Experimental procedures.” Actin was used as the loading control. 
(C) mRNA levels of Na+/inositol transporter SMIT1 and (D) H+/inositol 
transporter HMIT were measured as described above. 
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Phosphorylation of these sites inactivates GSK-3 kinase (Cross et al., 1995; 
Srivastava and Pandey, 1998). As seen in Fig. 4-2A, GSK-3α phosphorylation 
was increased in response to inhibition of inositol synthesis, while GSK3β was 
not significantly altered. GSK-3α phosphorylation was dependent on the level of 
Ino1 knockdown. Thus, an 82% decrease in Ino1 protein in shRNA-INO1-2 cells 
led to a 2.4-fold increase in GSK-3α phosphorylation, while a 60% decrease in 
shRNA-INO1-1 led to a 1.5-fold increase. These results indicated that decreasing 
the de novo synthesis of inositol led to GSK-3α inactivation.  
VPA-induced transient decrease in inositol is associated with GSK-3α 
inactivation. 
We have previously shown that the mood stabilizer VPA inhibits inositol 
synthesis in both yeast and human cells (Ju and Greenberg, 2003; Shaltiel et al., 
2004b; Vaden et al., 2001). If inositol depletion was the cause of inhibitory 
phosphorylation of GSK-3α as seen in Fig. 4-2A, VPA may be expected to cause 
a similar effect. To address this possibility, we assayed GSK-3 phosphorylation in 
cells treated with VPA. As seen in Fig. 4-4A, VPA caused a significant decrease 
in inositol levels in the first hour of exposure, after which inositol levels were 
restored. As predicted, GSK-3α phosphorylation was increased in response to 
VPA (Fig. 4-4B), while GSK-3β phosphorylation was not significantly affected. 
Interestingly, GSK-3α phosphorylation continued to increase after inositol levels 
were restored (Figs. 4-4A and 4-4B). It is likely that inositol levels are restored by 
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recycling of inositol from inositol phosphates, and maintaining inositol 
homeostasis is associated with the regulation of GSK-3α phosphorylation. 
 





Fig. 4-4: VPA decreases intracellular inositol and increases the 
inhibitory phosphorylation of GSK-3α. (A) Intracellular inositol levels 
were measured in SK-N-SH cells after exposure to VPA for the indicated 
times. (B) Western blot analysis of the protein levels of GSK-3α (Ser21) and 
GSK-3β (Ser9) and total protein levels of GSK-3α and GSK-3β.  Actin was 




Despite the importance of inositol, there are very few reported studies of the 
consequences of inositol depletion in human cells. Here, we report that inositol 
synthesis is essential for proliferation and neurite outgrowth of SK-N-SH human 
neuroblastoma cells, and that inhibition of inositol biosynthesis leads to GSK-3α 
inactivation.  
 
The interplay between inositol biosynthesis and GSK-3 activity reported in the 
current study has implications for understanding the therapeutic mechanisms of 
the mood-stabilizers used to treat bipolar disorder. Lithium and VPA are mood-
stabilizers with disparate chemical properties. Interestingly, both drugs have 
been shown to decrease cellular inositol content by blocking inositol biosynthesis, 
and both drugs also inhibit GSK-3 activity. Consistent with these findings, two 
prevailing hypotheses for the therapeutic mechanisms of action of these drugs 
are inositol depletion (Berridge et al., 1989) and GSK-3 inhibition (Klein and 
Melton, 1996). A potential link between inositol depletion and GSK-3 inhibition 
has not been previously tested in human cells. While the inositol depleting drug 
lithium leads to increased phosphorylation of GSK-3β   (Beaulieu et al., 2008; 
Zhang et al., 2003), we showed that VPA causes transient inositol depletion 
leading to increased phosphorylation of GSK-3α.  We further report a direct link 
between inositol synthesis and GSK-3 activity in neuronal cells. Specifically, 




Interestingly, while GSK-3α phosphorylation was increased in response to 
inositol depletion, GSK-3β was not significantly altered. Previous studies have 
shown that inhibitory phosphorylation and kinase activity of GSK-3 are affected 
by exposure to lithium and VPA (Beaulieu et al., 2008; Chen et al., 1999; Chen et 
al., 2006; De Sarno et al., 2002; Kim et al., 2005; Kim et al., 2013; Klein and 
Melton, 1996; Lucas and Salinas, 1997; Phiel et al., 2003; Ryves and Harwood, 
2001; Zhang et al., 2003). While some studies characterized the inhibitory effects 
of the drugs on both GSK-3α and GSK-3β, most have focused on the effects on 
GSK-3β. This is the first demonstration in SK-N-SH cells that a decrease in 
inositol biosynthesis led to the preferential inactivation of GSK-3α. Further 
studies are needed to elucidate the significance of the differential inhibition of 
GSK-3α and GSK-3β, which do not have identical functions.  
 
The inactivation of GSK-3α in SK-N-SH cells was dependent on the degree of 
Ino1 knockdown (Fig. 4-2). Interestingly, the degree of inactivation of GSK-3α 
also correlates with exposure times to VPA (Fig. 4-4B). While inhibition of inositol 
synthesis potently increases GSK-3α phosphorylation, inositol homeostasis is 
highly maintained, as intracellular inositol levels were restored upon prolonged 
exposure to VPA (Fig. 4-4A). It is likely that turnover of phosphatidylinositol 
and/or recycling of inositol phosphates are increased to compensate for 
decreased inositol biosynthesis. However, the mechanism whereby inhibition of 
inositol synthesis causes inactivation of GSK-3α activity (by increasing 
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phosphorylation of this kinase) remains unclear. Perturbation of inositol 
homeostasis resulting from disrupted inositol synthesis may modulate PI3K/AKT 
signaling. We speculate that inhibition of inositol synthesis activates the 
synthesis of PI3,4,5P3. The synthesis of PI3,4,5P3 is required for recruiting AKT, 
and the subsequent activation of AKT on the plasma membrane potently inhibits 
GSK-3 by phosphorylation (Cantley, 2002; Czech, 2003; Di Paolo and De Camilli, 
2006).  
 
Surprisingly, exogenous inositol did not regulate inositol biosynthesis or uptake 
by controlling expression of the inositol biosynthetic gene INO1 or the genes 
encoding inositol transporters SMIT1 and HMIT. In contrast, the transcription of 
INO1 and the inositol transporter genes in yeast cells is highly regulated in 
response to exogenous inositol, and inositol synthesis and uptake are modulated 
by this regulation (Henry et al., 2014; Hirsch and Henry, 1986; Lai et al., 1995; 
Lai and McGraw, 1994; Loewen et al., 2004). This indicates that neuronal cells 
have evolved different mechanisms to regulate inositol metabolism. For example, 
inositol uptake in mammals is regulated by glucose, pH, osmolality, and growth 
factors (Di Daniel et al., 2009; Fu et al., 2012; Miyakawa et al., 1999; Novak et al., 
1999; Olgemoller et al., 1993; Spizz and Pike, 1992; Uldry et al., 2004). While the 
genes encoding inositol transporters are not transcriptionally regulated in 
response to exogenous inositol in SK-N-SH cells, the activity of inositol uptake 
may be controlled by different mechanisms. Inositol synthesis in yeast is also 
regulated by the synthesis of inositol pyrophosphates (Ye et al., 2013) and the 
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glycolysis intermediate dihydroxyacetone phosphate (DHAP) (Migaud and Frost, 
1996; Shi et al., 2005), and requires GSK-3 (Azab et al., 2007). One or more of 
these mechanisms identified in yeast may also control inositol biosynthesis in 
mammalian cells.  
 
In summary, we showed that de novo inositol synthesis catalyzed by Ino1 is 
required for proliferation of SK-N-SH cells during inositol-deficient conditions and 
for GSK-3α activation. These findings have implications for understanding the 





















The importance of regulation of the synthesis of phospholipids is underscored by 
crucial roles of phospholipids in cellular functions, most notably in membrane 
biogenesis and cell signaling. The synthesis of phospholipids is highly regulated 
in response to cell growth, division, aging, or stress conditions. This regulation 
potently controls phospholipid composition in cellular membranes and generates 
specific lipids to relay signals. For example, cardiolipin (CL), the signature 
phospholipid of mitochondria, comprises about 10-15% of total mitochondrial 
phospholipids (Jakovcic et al., 1971; van Meer et al., 2008b), the levels of which 
are correlated with mitochondrial respiration (Claypool et al., 2008b; Gohil et al., 
2004; Jiang et al., 2000). Interestingly, the externalization of CL to the outer 
mitochondrial membrane is a signal for mitophagy in neuronal cells (Chu et al., 
2013). Phospholipids are not only structurally important components of cellular 
membranes, but they also act as signals for organelle homeostasis. The 
importance of phospholipids is further underscored by their roles in human 
disorders. For example, mutations in the tafazzin gene, which encodes the 
transacylase for CL remodeling, lead to the life-threatening disorder Barth 
syndrome (Barth et al., 1983; Barth et al., 2004; Barth et al., 1999). Therefore, 
understanding the regulation of synthesis of phospholipids will shed light on our 
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fundamental knowledge of cell biology as well as human health. Chapters 2 and 
3 in this dissertation describe novel mechanisms underlying the regulation of 
phospholipid synthesis, and Chapter 4 describes the consequence of inhibition of 
the synthesis of inositol, a percursor of inositol lipids. New questions wait to be 
addressed. I challenge future students to push the limit of our knowledge of lipid 
biology by addressing the following questions. 
 
1. How is inositol pyrophosphate kinase Kcs1 regulated to control 
inositol biosynthesis? 
 
In Chapter 2, I showed that the control of INO1 expression in response to inositol 
is associated with Kcs1 protein levels (Fig. 2-7). However, KCS1 mRNA levels 
are not altered in response to inositol (Fig. 2-7C), suggesting that Kcs1 protein is 
controlled at the level of translation, post-translational modification, and/or 
stability of Kcs1 protein. The underlying mechanisms by which Kcs1 protein 
levels respond to exogenous inositol are unclear, and it remains to be 
determined if the levels of inositol pyrophosphates are altered in response to 
exogenous inositol. 
I have also shown that the DNA-interacting bZIP domain of the Kcs1 protein is 
required for INO1 expression and inositol synthesis (Fig. 2-5), suggesting that 
Kcs1 may directly interact with the chromatin region of INO1. Recently, IP6K1, 
the mammalian homolog of Kcs1, has been shown to interact with chromatin and 
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regulate histone methylation (Burton et al., 2013). While regulation of histone 
modifications influences gene transcription, it is not clear if Kcs1-mediated 
regulation of INO1 expression involves the interaction of Kcs1 with the chromatin 
region of the INO1 promoter, and/or methylation of the region.  
Further investigations may elucidate a molecular mechanism underlying how 
inositol pyrophosphates regulate inositol synthesis by modulating INO1 
expression.  
 
2. Is the mechanism whereby inositol pyrophosphates regulate inositol 
biosynthesis conserved in mammals? 
 
Chapter 2 describes a mechanism whereby inositol synthesis is regulated by 
inositol pyrophosphates in the yeast Saccharomyces cerevisiae. Specifically, 
Kcs1, which catalyzes synthesis of inositol pyrophosphates, modulates INO1 
expression. While this finding demonstrates a new level of complexity of 
regulation of inositol synthesis, it is unclear if this regulation is conserved from 
yeast to mammals.  
Mammalian Ino1 has four putative mRNA isoforms (α, β, γ, and δ) derived from 
alternative splicing, of which the α isoform is the full-length Ino1 mRNA (Seelan 
et al., 2009). These isoforms exhibit tissue specificity (Guan et al., 2003; Seelan 
et al., 2009). However, regulation of expression of INO1 isoforms has not been 
rigorously studied in mammals. My preliminary studies (not discussed in Chapter 
 133 
2) indicate that total Ino1 protein was increased, and the γ isoform was 
expressed in IP6K1 knockout mouse embryonic fibroblasts (MEF). Consistent 
with the increase in Ino1 protein, INO1 mRNA levels were also increased in 
these cells. Therefore, regulation of INO1 expression in inositol pyrophosphate-
deficient mammalian cells is different from that in yeast cells. We further 
determined the activity of inositol synthesis in crude cell extracts of wild type and 
IP6K1 knockout cells. Surprisingly, inositol synthesis was significantly decreased 
in IP6K1 knockout cells. Therefore, the finding that inositol pyrophosphate 
deficiency leads to decreased inositol synthesis is conserved from yeast to 
mammals, although the regulation of INO1 expression is disparate. It is unclear 
how inositol synthesis is decreased in IP6K1 knockout cells in spite of increased 
INO1 expression. I am currently addressing two questions regarding this 
regulatory mechanism. First, how does IP6K1 regulate INO1 transcription? 
Second, how is Ino1 activity regulated in IP6K1 knockout cells?  
Elucidating how inositol synthesis is controlled by inositol pyrophosphates may 








3. What is the mechanistic link between inositol biosynthesis and GSK-
3 activity? 
 
 In Chapter 4, I described a novel interplay between inositol synthesis and GSK-
3α phosphorylation in SK-N-SH neuronal cells. Specifically, inhibition of inositol 
biosynthesis by shRNA-mediated knockdown of INO1 expression or by VPA 
treatment leads to increased inhibitory phosphorylation of GSK-3α. However, the 
mechanism whereby inhibition of inositol synthesis causes increased 
phosphorylation of GSK-3α remains unclear. My current hypothesis is that 
decreasing inositol synthesis activates PI3K/AKT signaling, which regulates 
phosphorylation of GSK-3. PI3K kinase coverts PI4,5P2 to PI3,4,5P3, which is 
required for recruiting AKT to the plasma membrane. Activation of AKT on the 
plasma membrane potently inhibits GSK-3 by phosphorylation (Cantley, 2002; 
Czech, 2003; Di Paolo and De Camilli, 2006). We speculate that inositol 
depletion may modulate the synthesis of PI3,4,5P3 by affecting the enzymatic 
activity or protein levels of PI3K kinase. The mechanism whereby inositol 
depletion causes GSK-3 inhibition has implications for understanding the 






4. What are the functions of CL remodeling? 
 
In Chapter 3, we have shown that deletion of the CL-specific phospholipase Cld1 
rescues growth and lifespan defects in the tafazzin mutant, and that Cld1 
regulation in response to mitochondrial respiration modulates energy dynamics. 
The finding that deletion of Cld1 alleviates the deleterious effects of the loss of 
tafazzin suggests that CL-specific phospholipases may be potential targets for 
treating BTHS patients. However, CL-specific phospholipases have not been 
identified in mammals. We have received funding from the Barth Syndrome 
Foundation for a project entitled “Identification of human CL phospholipases that 
are deleterious to tafazzin-deficient cells,” which proposes to identify potential 
phospholipases that deacylate CL. Characterization of human CL 
phospholipases may identify potential therapeutic targets for treating BTHS 
patients. 
While our studies showed that regulation of the phospholipase Cld1 responds to 
mitochondrial respiration and modulates energy dynamics, this raises the 
question of what is the function of CL remodeling, and the corollary question of 
why is CLD1 expression increased in response to respiration. Because 
superoxides generated from mitochondrial respiration can impair CL functions by 
peroxidation of CL (Paradies et al., 2000; Paradies et al., 2001; Paradies et al., 
1998), we speculate that one possible function of deacylation of CL is to remove 
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peroxidized CL. In this model, CL remodeling acts as a mechanism whereby 
damaged fatty acyl chains are replaced. To test this possibility, the specificity of 
Cld1 enzymatic activity for peroxidized CL can be assayed in vitro. Although the 
cld1Δ mutant grows normally under respiratory conditions (Fig. 4-2), it is not clear 
if cld1Δ is sensitive to ROS-inducing reagents, such as H2O2. Elucidating the 
potential role of Cld1 in deacylating peroxidized CL may identify an exciting 
physiological function of CL remodeling.    
While Cld1 regulation may remediate the deleterious effects of respiration by 
replacing peroxidized CL, the role of CL remodeling is largely not understood. A 
powerful tool to elucidate function is that of identifying genetic interaction with the 
gene in question.  Synthetic genetic array (SGA) analysis is a yeast-based high-
throughput assay to identify genetic interactions, which yields unbiased functional 
information pertaining to a query strain. I am currently in the process of carrying 
out an SGA analysis using the cld1Δ mutant as the query strain crossed with the 
entire genome deletion set.  While the remodeling of CL is disrupted in both 
cld1Δ and taz1Δ mutants, CL levels are not affected in cld1Δ. Therefore, this 
SGA analysis using cld1Δ as the query strain will hopefully identify genetic 
interactions that are due to the loss of CL remodeling but not to decreased CL. A 
complete list of genes that genetically interact with CLD1 will be available from 
this study. I encourage future students to investigate the function of CL 
remodeling based on these genetic findings.  
While we are approaching the end of this dissertation, we have certainly not 
finished our discussion of what makes studying the regulation of the synthesis of 
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inositol and cardiolipin so exciting. No doubt my labmates will enjoy the science 
in our wonderful lab with unbeatable spirit. If you ever wonder where science will 
take you, my answer is to enjoy the journey, because science is full of beauty 
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        Phospholipids are the most abundant lipids in cell membranes. The 
synthesis of phospholipids is crucial for cellular membrane biogenesis and nearly 
all aspects of cellular processes. Understanding the regulation of synthesis of 
phospholipids is beneficial to our fundamental knowledge of cell biology as well 
as human health. 
        Regulation of the synthesis of phospholipids is intensively studied in the 
yeast S. cerevisiae. Most notably, the synthesis of phospholipids is coordinated 
with the synthesis of inositol, a precursor of inositol-containing lipids, by 
controlling expression of the genes encoding phospholipid biosynthetic enzymes. 
In addition to this well-characterized regulatory circuit controlled by the trans-
acting factors Ino2, Ino4, and Opi1, this dissertation shows that inositol 
 174 
pyrophosphates are novel regulators of the synthesis of inositol and 
phosphatidylinositol that control INO1 expression. 
        Despite the importance of inositol, there are very few reported studies of the 
cellular consequences of perturbation of inositol synthesis in human cells. 
Studies of SK-N-SH neuronal cells in this dissertation demonstrate that inositol 
biosynthesis is essential for cell proliferation and neurite outgrowth, and inhibition 
of inositol biosynthesis leads to inactivated GSK-3α,  which  has  many  regulatory  
functions in neural systems. This novel finding bridges two prevailing hypotheses 
of inositol depletion and GSK-3 inhibition and suggests a unifying hypothesis for 
the therapeutic mechanisms of action of mood-stabilizing drugs. 
        Although the synthesis of most phospholipids (phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol) is 
responsive to inositol, the synthesis of cardiolipin (CL) is an exception. 
Characterization of the regulation of CL synthesis has unveiled the critical role of 
CL remodeling via the regulation of the CL-specific phospholipase Cld1. 
Transcriptional regulation of Cld1-mediated deacylation of CL influences energy 
metabolism by modulating the relative contribution of glycolysis and respiration to 
ATP production. Interestingly, CLD1 expression is responsible for defective 
growth and respiration in tafazzin-deficient cells. We demonstrate that these 
underlying defects of tafazzin deficiency are caused by the decreased CL/MLCL 
ratio, not by a deficiency in unsaturated CL. These findings have significant 
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